EXPANDING
the Spectrum of Genomic Health
Dedicated to clinical excellence in the field of genetics.

With over four decades of innovation, our test menu of over 450 genetic tests is one of the most comprehensive in the industry today, including:

- Prenatal genetics
- Molecular genetics
- Biochemical genetics
- Cytogenetics
- Oncology-related genetics

Visit our booth #207
Welcome to Boston!

On behalf of the NSGC Annual Education Conference (AEC) Planning Subcommittee and the NSGC Board of Directors, thank you for joining us in Boston!

NSGC is expanding the spectrum of genomic health with more than 30 educational sessions designed to support your professional development. Session topics include genetic counseling research, ethical issues in genetic testing, personalized medicine and other topics on the forefront of genetics. Education highlights you will not want to miss include the Clinical Doctorate Plenary Session (page 13), the Dr. Beverly Rollnick Memorial Lecture (page 15) and the NSGC Professional Issues Panel (page 14). Reference pages 11-16 for sessions submitted/sponsored by your NSGC Special Interest Group. Make the most of your AEC schedule and plan to attend education sessions specific to your professional interests.

Expanding your expertise and professional development goes far beyond the valuable education taking place behind the lecture room walls. We encourage you to maximize your AEC experience and take advantage of the Welcome Reception, SIG meetings and other networking opportunities available to you this week. Visit the Exhibitor Suite to see the latest product offerings and services from our industry partners. Catch up with old friends and make new contacts during receptions, program reunions and daily breaks. Attend the NSGC and ABGC Business Meetings to learn more about the latest efforts of your professional organizations. There are so many ways to make this week an incredible experience!

We hope you enjoy your time here in Boston. Take time to learn and connect as we reflect on the advances of the past year and look to the future of genomics in this amazing city!

Claire N. Singletary, MS, CGC
2012 AEC Chair

Quinn Stein, MS, CGC
2012 AEC Vice-Chair

Table of Contents
About the AEC ...........................................4
General Information .....................................5
AEC Schedule-at-a-Glance ..........................6
Hynes Convention Center Floor Plan ...........8
AEC Session Objectives ...............................11
Concurrent Papers ....................................18
Posters ......................................................21
Thank You to Our Sponsors .....................27
NSGC Awards and Fellowships ..................28
AEC Planning Subcommittee .....................28
Networking Activities and Business Meetings ..................................................30
Exhibitor Directory ..................................32
Exhibitor Suite Map ..................................33
Exhibitor Index ........................................35

Download the free 2012 NSGC AEC Mobile App!

This new, easy-to-use mobile app contains program information, the schedule-at-a-glance, educational content, maps and more!

See page 26 for more details.
Statement of Purpose
The 31st Annual Education Conference (AEC) focuses specifically on the educational needs of genetic counselors. The AEC addresses a wide variety of genetic counseling practice areas and provides the latest information for the genetic counseling profession. Attendees will have access to education designed to support and enhance their current practice. The Pre-conference Symposia will provide current information, products and services and the opportunity to talk with exhibitors about new developments in the genetic counseling field. The Pre-conference Symposia will provide in-depth information on specific topics relevant to the field of genetic counseling.

Continuing Education Units
The National Society of Genetic Counselors has been approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102. The National Society of Genetic Counselors is authorized by IACET to offer up to 3.23 Category 1 CEUs or up to 32.25 Category 1 Contact Hours for the 31st Annual Education Conference. CEUs and Contact hours offered by NSGC will be accepted by The American Board of Genetic Counseling (ABGC) for genetic counselor recertification.

To receive CEUs for a session, attendees must be present for the entire session. The total number of CEUs awarded will be determined by the number of sessions an individual attends. To earn CEUs, attendees MUST:
1. Scan the bar code on the attendee badge upon entering each CEU eligible session.
2. Report and indicate all sessions attended in the online system.
3. Complete an online electronic session evaluation for each session that is attended.

Per IACET requirements, completion of these three steps is mandatory for individuals to receive CEU/Contact Hour credit.

Attendees must retain a copy of this certificate for their records for five years from the date of the course. This form will serve as final Proof of Completion.

IACET requires NSGC to track attendance in sessions for those seeking continuing education credits. To replace the previously used sign-in sheets, there will be a scanner outside of each session room to scan the bar code on your attendee badge upon entering the room. Scanners will be outside of the session rooms for 10 minutes past the start time of the session. If you miss your opportunity to scan in, please see the registration desk to add your name to a session.

IMPORTANT: NSGC will issue a CEU confirmation e-mail following the conference. NSGC will only be able to verify the credits you earned by the portion of the sessions marked as “attended” in the online system.

Evaluation Process
Please assist NSGC in evaluating the AEC sessions and provide valuable input that will help NSGC plan future conferences.

Educational Session Evaluations
Participants are asked to complete online evaluations to provide input regarding individual speakers and educational content. We ask all attendees to complete an online session evaluation for each session attended. Although individuals requesting CEUs MUST complete evaluations, NSGC would greatly appreciate feedback from all attendees.

Poster Evaluation
Participants may also complete an electronic Poster Evaluation Form to evaluate the posters displayed. Those seeking CEUs for viewing posters MUST complete a Poster Evaluation form.

Concurrent Papers Evaluation
Concurrent papers feature six back-to-back presentations in four different categories running concurrently. The speaker in the first time slot is considered speaker 1, the speaker in the second time slot is considered speaker 2, and so on.

Evaluating various speakers:
If you plan to attend all six abstracts within the same category (no room change), complete just one electronic evaluation by filling in the session code and evaluating speakers 1 thru 6. If you plan to change categories/rooms between abstracts and would like to evaluate each speaker, you may complete up to four evaluations (one for each category, depending how many you attend). For each category, fill in the appropriate session code and then evaluate each speaker based on which time slot they presented in. The speaker in the first time slot is speaker 1, the speaker in the second time slot is speaker 2, and so on.

NOTE: To claim CEUs, you only need to complete one electronic evaluation for one category/session. You will claim the same session as “attended” in the online system.

Overall Conference Evaluation
Following the AEC, you will receive an electronic survey by e-mail requesting feedback about your overall conference experience. Please take a moment to complete this brief survey as your feedback is integral in planning future NSGC events.

Executive Office Information
NSGC Executive Office
401 N. Michigan Ave.
Suite 2200
Chicago, IL 60611 USA
Phone: 312.321.6834
Fax: 312.673.6972
Email: nsgc@nsgc.org
Website: www.nsgc.org

All online electronic forms can be found at https://www.showreg.net/NSGC1210S/CEUCreditLogin.asp.
Registration Hours

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, October 23</td>
<td>5:00 pm – 8:00 pm</td>
</tr>
<tr>
<td>Wednesday, October 24</td>
<td>7:00 am – 8:00 pm</td>
</tr>
<tr>
<td>Thursday, October 25</td>
<td>6:30 am – 7:30 pm</td>
</tr>
<tr>
<td>Friday, October 26</td>
<td>6:30 am – 7:30 pm</td>
</tr>
<tr>
<td>Saturday, October 27</td>
<td>6:30 am – 2:00 pm</td>
</tr>
</tbody>
</table>

Exhibitor Suite Hours

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, October 24</td>
<td>6:15 pm – 8:15 pm</td>
</tr>
<tr>
<td>Thursday, October 25</td>
<td>11:00 am – 2:00 pm</td>
</tr>
<tr>
<td></td>
<td>5:30 pm – 7:30 pm</td>
</tr>
<tr>
<td>Friday, October 26</td>
<td>11:30 am – 4:00 pm</td>
</tr>
</tbody>
</table>

Message Center and Job Boards

Bulletin boards with push-pins are available for attendees to leave messages for colleagues or post job opportunities within the genetic counseling field. Advertising is not permitted. Materials posted will be monitored and inappropriate information is subject to removal.

Attendee List Information

Attendee lists are posted on the NSGC website prior to the conference, and an updated list will be posted after the conference. Lists are posted on a board in the Registration Area and are available for making copies (at the attendee’s expense) at the Business Center on the Plaza Level near the South Lobby. Attendee lists may not be used for solicitation purposes other than networking. NSGC is not responsible for errors and/or omissions.

Handouts and Presentations

NSGC offers electronic versions of AEC handouts. NSGC does not provide paper copies of AEC session handouts at the conference. All session handouts (if provided by the speaker) are posted on the NSGC Website and will be available following the conference until March 1, 2013. To download handouts go to http://www.nsgc.org/2012AECHandouts/tabid/490/Default.aspx or use this QR Code.

If you are also registered for a Pre-conference Symposium, you will be given a separate link to access these handouts. Handouts will also be available for making copies (at the attendee’s expense) in the Business Center.

Business Center Hours of Operation

<table>
<thead>
<tr>
<th>Days</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday – Friday</td>
<td>7:00 am – 7:00 pm</td>
</tr>
<tr>
<td>Saturday and Sunday</td>
<td>7:00 am – 5:00 pm</td>
</tr>
</tbody>
</table>

Internet Access

Hotel

All NSGC attendees who stay at the Boston Marriott or the Sheraton Boston will receive a discounted rate for internet access in their guest rooms.

Convention Center

The Hynes Convention Center offers free wireless internet service throughout meeting rooms, lobbies and expo halls. Open your internet browser, and look for the “BCEC” or “Hynes Wireless Network.” This service is designed for casual use and is not guaranteed.

Attendees will also have complimentary access to the AEC Internet Pavilion in the Hynes Convention Center throughout the duration of the AEC. The Internet Pavilion is located on the third floor of the convention center.

Sponsored Breakfast, Lunch and Evening Sessions

Sponsored breakfast, lunch and evening sessions are open to the first 300 attendees and are located in the Hynes Convention Center, Room 312. Refer to the session objectives, pages 11-16. Continuing Education Unit approval is noted for eligible sessions.

2012 AEC Online Session Recordings

Maximize your AEC experience! View the sessions you missed in Boston, earn additional CEUs or access the valuable information you gathered on site. Take advantage of the opportunity to purchase the online session recordings — order today!

Session recording packages featuring all Pre-conference Symposia*, or featuring the AEC Plenary and EBS sessions*, are available for purchase. The online recordings will contain synched audio and PowerPoint® presentations for each session. To earn Category 1 CEUs, it is required that you complete and pass a quiz included at the conclusion of each session. Purchase your online recording package in conjunction with your AEC registration for a special discounted rate.**

If you register for the AEC only:

- AEC recordings — $59
- Pre-conference Symposia recordings — $119

If you register for a Pre-conference Symposium only:

- AEC recordings — $119
- Pre-conference Symposia recordings — $59

Best Combo Deal!

If you register for the AEC and Pre-conference Symposium:

- Receive both the Pre-conference Symposia and AEC recordings for the special package price of $99.

Registered attendees are able to order online content both during the AEC and following the conference at an increased rate. Not attending the AEC? Check the NSGC website in January 2013 for additional information and purchase availability.

* With speaker approval

** Discounted package rates only available when purchased in conjunction with a conference registration.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 pm – 6:30 pm</td>
<td>Moderator Orientation – Room 301</td>
<td></td>
</tr>
<tr>
<td>7:00 am – 7:30 am</td>
<td>Moderator Orientation – Room 301</td>
<td></td>
</tr>
<tr>
<td>8:00 am – 2:00 pm</td>
<td>Pre-conference Symposia</td>
<td></td>
</tr>
<tr>
<td>3:45 pm – 5:15 pm</td>
<td>Various Committee and Task Force Meetings</td>
<td></td>
</tr>
<tr>
<td>6:00 pm – 7:30 pm</td>
<td>Welcome Reception in Exhibitor Suite – Room 302/304/306</td>
<td></td>
</tr>
<tr>
<td>8:00 pm – 9:00 pm</td>
<td>Welcome Reception in Exhibitor Suite – Hall D</td>
<td></td>
</tr>
</tbody>
</table>

**Tuesday, October 23**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am – 2:00 pm</td>
<td>101 – Disorders of Sex Development: A Multidisciplinary Approach to Diagnosis, Treatment, and Management of Care</td>
<td>Room 201, See page 11</td>
</tr>
<tr>
<td>8:00 am – 2:00 pm</td>
<td>102 – Surgical Management for Inherited Cancer Syndromes: Understanding the Options and Effects on Quality of Life</td>
<td>Room 207, See page 11</td>
</tr>
<tr>
<td>8:00 am – 2:00 pm</td>
<td>103 – Measuring Patient Outcomes of Genetic Counseling: Why It’s Important, How to Do It, and What Outcomes to Assess</td>
<td>Room 203, See page 11</td>
</tr>
<tr>
<td>8:00 am – 2:00 pm</td>
<td>104 – The Impact of NextGen Sequencing of Cell-Free DNA on Prenatal Genetic Counseling</td>
<td>Room 302/304/306, See page 11</td>
</tr>
<tr>
<td>8:00 am – 2:00 pm</td>
<td>105 – Epigenetics: Why DNA Sequence Isn’t Everything</td>
<td>Room 204, See page 11</td>
</tr>
<tr>
<td>8:00 am – 2:00 pm</td>
<td>106 – Universal Genetic Counseling Issues Viewed Through a Cardiovascular Lens</td>
<td>Room 202, See page 11</td>
</tr>
<tr>
<td>2:00 pm – 3:00 pm</td>
<td>NSGC 2013 Leadership Development Workshop – Room 305</td>
<td></td>
</tr>
<tr>
<td>2:00 pm – 3:00 pm</td>
<td>Welcome to the AEC – Room 207</td>
<td></td>
</tr>
<tr>
<td>3:30 pm – 4:30 pm</td>
<td>Opening Remarks – Room 302/304/306</td>
<td></td>
</tr>
<tr>
<td>4:30 pm – 5:30 pm</td>
<td>Beth Fine Kaplan Best Student Abstract Award 110 – Exploring the Relationship Between Diagnoses of Congenital Anomalies or Genetic Conditions and Postpartum Depression: A Retrospective Study</td>
<td>Room 302/304/306, See page 12</td>
</tr>
<tr>
<td>5:30 pm – 6:30 pm</td>
<td>107 – Practical Guidelines for Managing Patients with The 22q11.2 Deletion Syndrome</td>
<td>Room 302/304/306, See page 11</td>
</tr>
<tr>
<td>5:30 pm – 6:30 pm</td>
<td>108 – Complexities of Hereditary Pancreatitis: Clinical Review and Genetic Counseling Implications for Your Practice</td>
<td>Room 302/304/306, See page 11</td>
</tr>
<tr>
<td>5:30 pm – 6:30 pm</td>
<td>109 – An Overview of Very Long Chain Acyl-CoA Dehydrogenase Deficiency, Current Management and Developing Therapeutic Options</td>
<td>Room 302/304/306, See page 12</td>
</tr>
<tr>
<td>6:00 pm – 6:30 pm</td>
<td>Natalie Weissberger Paul Award and Audrey Heimler Special Project Award – Room 302/304/306, See page 28</td>
<td></td>
</tr>
<tr>
<td>6:15 pm – 8:15 pm</td>
<td>Exhibitor Suite Open – Hall D</td>
<td></td>
</tr>
<tr>
<td>8:00 pm – 9:00 pm</td>
<td>Welcome Reception in Exhibitor Suite – Hall D</td>
<td></td>
</tr>
</tbody>
</table>

**Wednesday, October 24**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 pm – 9:00 pm</td>
<td>201 – Pan-ethnic Expanded Carrier Screening</td>
<td>Room 210, See page 12</td>
</tr>
<tr>
<td>8:00 pm – 9:00 pm</td>
<td>202 – Dissecting the Utility of MSI/IGH on Colon Polyps and Extracolonic Cancers</td>
<td>Room 302/304/306, See page 12</td>
</tr>
<tr>
<td>8:00 pm – 9:00 pm</td>
<td>203 – Building a Brain: Understanding and Researching the Genetics of Brain Development and Function</td>
<td>Room 207, See page 12</td>
</tr>
<tr>
<td>8:00 pm – 9:00 pm</td>
<td>204 – The Future is Now: The Impact of Next Generation Sequencing as Applied to Whole Exome and Whole Genome Sequencing on the Diagnostic Laboratory and Clinical Practice</td>
<td>Room 205, See page 12</td>
</tr>
<tr>
<td>10:15 am – 10:45 am</td>
<td>NSGC State of the Society Address – Room 302/304/306, See page 30</td>
<td></td>
</tr>
<tr>
<td>10:45 am – 12:15 pm</td>
<td>205 – The Future is Now: The Impact of Next Generation Sequencing as Applied to Whole Exome and Whole Genome Sequencing on the Diagnostic Laboratory and Clinical Practice</td>
<td>Room 205, See page 12</td>
</tr>
<tr>
<td>11:00 am – 1:00 pm</td>
<td>Plenary Session 206 – The Clinical Doctorate – Room 302/304/306, See page 13</td>
<td></td>
</tr>
<tr>
<td>12:00 pm – 2:15 pm</td>
<td>Various Committee and Task Force Meetings</td>
<td></td>
</tr>
<tr>
<td>12:00 pm – 2:15 pm</td>
<td>Various Special Interest Group Meetings</td>
<td></td>
</tr>
<tr>
<td>12:30 pm – 2:00 pm</td>
<td>Various Committee and Task Force Meetings</td>
<td></td>
</tr>
<tr>
<td>2:15 pm – 4:15 pm</td>
<td>Educational Breakout Sessions</td>
<td></td>
</tr>
<tr>
<td>3:40 pm – 5:15 pm</td>
<td>Plenary Session 212 – Clinical Genetic Resources at NCBI – Room 302/304/306, See page 13</td>
<td></td>
</tr>
<tr>
<td>5:15 pm – 6:00 pm</td>
<td>Plenary Session 213 – Running with the Tray: Ethical and Societal Implications of Mandatory Testing of Athletes for Sickle Cell Trait – Room 302/304/306, See page 13</td>
<td></td>
</tr>
<tr>
<td>5:30 pm – 7:30 pm</td>
<td>Exhibitor Suite Open – Hall D</td>
<td></td>
</tr>
<tr>
<td>6:00 pm – 7:30 pm</td>
<td>Posters with Authors Session 214 – Hall D, See page 21</td>
<td></td>
</tr>
</tbody>
</table>
### Thursday, October 25 (continued)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 pm – 8:00 pm</td>
<td>International SIG Meeting – Room 311</td>
<td>Room 311</td>
</tr>
<tr>
<td>7:30 pm – 9:00 pm</td>
<td>University of Pittsburgh Reunion – Room 200</td>
<td>Room 200</td>
</tr>
<tr>
<td>7:30 pm – 9:00 pm</td>
<td>Sponsored Evening Session 215 – Termination of Pregnancy for Indications of Genetic Disorder and Fetal Abnormality in Advanced Gestations at Boulder Abortion Clinic, Sponsored by Boulder Abortion Clinic, P.C. – Room 312, See page 14</td>
<td>Room 312</td>
</tr>
<tr>
<td>8:00 pm – 9:00 pm</td>
<td>Telegenetics SIG Meeting – Room 311</td>
<td>Room 311</td>
</tr>
<tr>
<td>8:00 pm – 10:00 pm</td>
<td>Sarah Lawrence College Reception – Room 210</td>
<td>Room 210</td>
</tr>
<tr>
<td>8:30 pm – 10:00 pm</td>
<td>Mount Sinai Reunion – Room 207</td>
<td>Room 207</td>
</tr>
<tr>
<td>9:00 pm – 10:30 pm</td>
<td>University of Minnesota Reunion – Fairfax Room, Sheraton Boston</td>
<td>Fairfax Room, Sheraton Boston</td>
</tr>
</tbody>
</table>

#### Friday, October 26

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am – 7:30 am</td>
<td>Moderator Orientation – Room 301</td>
<td>Room 301</td>
</tr>
<tr>
<td>7:00 am – 7:45 am</td>
<td>Past Board Member Breakfast – Room 205</td>
<td>Room 205</td>
</tr>
<tr>
<td>7:00 am – 7:45 am</td>
<td>Sponsored Breakfast Session 301 – Non-Invasive Prenatal Testing: A New Era for Trisomy Detection, Sponsored by Integrated Genetics – Room 312, See page 14</td>
<td>Room 312</td>
</tr>
<tr>
<td>8:00 am – 9:00 am</td>
<td>Plenary Session 302 – Professional Issues Panel, Room 302/304/306, See page 14</td>
<td>Room 302/304/306</td>
</tr>
<tr>
<td>9:00 am – 9:45 am</td>
<td>Plenary Session 303 – Non-Invasive Prenatal Diagnosis Beyond Trisomy 21, Room 302/304/306, See page 14</td>
<td>Room 302/304/306</td>
</tr>
<tr>
<td>10:00 am – 12:00 pm</td>
<td>Educational Breakout Sessions</td>
<td>Room 302/304/306</td>
</tr>
<tr>
<td>11:30 am – 4:00 pm</td>
<td>Various Committee Meetings</td>
<td>Room 302/304/306</td>
</tr>
<tr>
<td>11:45 am – 2:00 pm</td>
<td>Public Policy Committee, 11:45 am – 12:45 pm, Room 209</td>
<td>Room 209</td>
</tr>
<tr>
<td></td>
<td>Practice Guidelines Committee, 11:45 am – 1:45 pm, Room 205</td>
<td>Room 205</td>
</tr>
<tr>
<td></td>
<td>Perspectives in Genetic Counseling (PGC) Committee, 12:15 pm – 1:15 pm</td>
<td>Room 208</td>
</tr>
<tr>
<td></td>
<td>Various Special Interest Group Meetings</td>
<td>Room 209</td>
</tr>
<tr>
<td>12:00 pm – 1:00 pm</td>
<td>Texas Society of Genetic Counselors – Room 305</td>
<td>Room 305</td>
</tr>
<tr>
<td>12:15 pm – 1:45 pm</td>
<td>Sponsored Lunch Session 308 – Hereditary Cancer Panels: Review of Initial Results and Discussion about Counseling for Next-Generation Tests, Sponsored by Ambry Genetics – Room 312, See page 15</td>
<td>Room 312, See page 15</td>
</tr>
<tr>
<td>2:00 pm – 3:30 pm</td>
<td>Concurrent Papers Sessions 309-312 – (See session grid on page 18 for room assignments)</td>
<td>Room 302/304/306</td>
</tr>
<tr>
<td>3:45 pm – 4:00 pm</td>
<td>Passport to Prizes Drawing – Hall D</td>
<td>Hall D</td>
</tr>
<tr>
<td>4:00 pm – 4:45 pm</td>
<td>NSGC Annual Business Meeting – Room 302/304/306, See page 30</td>
<td>Room 302/304/306</td>
</tr>
<tr>
<td>4:45 pm – 5:30 pm</td>
<td>NSGC Leadership Awards – Room 302/304/306, See page 28</td>
<td>Room 302/304/306</td>
</tr>
<tr>
<td>5:30 pm – 7:00 pm</td>
<td>Dr. Beverly Rollnick Lecture 313 – Part 1: That's Just Crazy Talk: A Play and Discussion; Part 2: Research Evaluation of a Play as a Stigma-Reduction Intervention – Room 302/304/306, See page 15</td>
<td>Room 302/304/306</td>
</tr>
<tr>
<td>7:00 pm – 8:00 pm</td>
<td>Metabolic/LSD SIG – Room 209</td>
<td>Room 209</td>
</tr>
<tr>
<td>7:15 pm – 8:45 pm</td>
<td>Sponsored Evening Session 314 – When More Isn't Better...Genetic Testing from a Legal Perspective, Sponsored by Quest Diagnostics – Room 312, See page 15</td>
<td>Room 312, See page 15</td>
</tr>
<tr>
<td>7:30 pm</td>
<td>Brandeis Reunion – Brandeis University</td>
<td>Hall D</td>
</tr>
</tbody>
</table>

#### Saturday, October 27

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am – 7:45 am</td>
<td>Sponsored Breakfast Session 401 – When Bigger is Better: Multi-gene Testing Panels for Genetically Heterogeneous Disorders, Sponsored by GeneDx – Room 312, See page 15</td>
<td>Room 312, See page 15</td>
</tr>
<tr>
<td>8:00 am – 9:00 am</td>
<td>Plenary Session 402 – Late Breaking: Targeted Pharmaceuticals for Neurodevelopmental Disorders – Room 302/304/306, See page 15</td>
<td>Room 302/304/306</td>
</tr>
<tr>
<td>9:00 am – 9:30 am</td>
<td>Incoming Presidential Address – Room 302/304/306, See page 30</td>
<td>Room 302/304/306</td>
</tr>
<tr>
<td>9:30 am – 10:30 am</td>
<td>Plenary Session 403 – Jane Engelberg Memorial Fellowship (JEMF) Presentation – Room 302/304/306, See page 15</td>
<td>Room 302/304/306</td>
</tr>
<tr>
<td>10:30 am – 12:30 pm</td>
<td>Educational Breakout Sessions</td>
<td>Room 302/304/306</td>
</tr>
<tr>
<td>12:30 pm – 2:00 pm</td>
<td>Sponsored Lunch Session 408 – Using Cost Effectiveness Modeling to Demonstrate the Value of Genetic Services, Sponsored by Myriad Genetic Laboratories, Inc. – Room 312, See page 16</td>
<td>Room 312, See page 16</td>
</tr>
<tr>
<td>12:30 pm – 2:00 pm</td>
<td>ABGC Annual Business Meeting – Room 302/304/306, See page 30</td>
<td>Room 302/304/306</td>
</tr>
<tr>
<td>12:30 pm – 2:15 pm</td>
<td>Various Group Meetings</td>
<td>Room 302/304/306</td>
</tr>
<tr>
<td>2:00 pm – 3:30 pm</td>
<td>Concurrent Papers Sessions 409-412 – (See session grid on page 19 for room assignments)</td>
<td>Room 302/304/306</td>
</tr>
</tbody>
</table>
**Clear**
Developed by Sequenom CMM, the technology and data behind the MaterniT21 PLUS test are extensively studied and well published.

**Convenient**
A noninvasive laboratory-developed test that can be used in the 1st or 2nd trimester, as early as 10 weeks’ gestation.
- Commercial experience with thousands of tests
- Genetic counselors available to consult about our testing services
- Customer service and support are available to answer your questions

**Compelling**
The MaterniT21 PLUS test detects fetal chromosomal 21, 18, 13 aneuploidies, and the presence of the Y chromosome, in singletons, twins and higher order multiple pregnancies.

**Learn More**
For more information, or to have a Business Development Manager contact you, please call us toll-free (within the US) at 877.821.7266
Visit www.SequenomCMM.com

---
Clarity for cancer.

Hereditary cancer testing from Ambry Genetics delivers real results. Our panels for hereditary breast, ovarian, colon and other cancers are helping clinicians—and their patients—discover answers to help guide important management decisions. To learn more stop by the Ambry booth (*109) at NSGC or visit ambrygen.com

DON’T MISS AMBRY’S SPONSORED LUNCH AT NSGC

Hereditary Cancer Panels: Review of Initial Results and Discussion About Counseling for Next-Generation Tests
Friday, October 26, 2012
12:15 - 1:45 pm
Pre-conference Symposia

Wednesday, October 24

8:00 am – 2:00 pm

101 Disorders of Sex Development: A Multidisciplinary Approach to Diagnosis, Treatment and Management of Care

0.50 CEU

1. V. Reid Sutton, MD, Department of Molecular & Human Genetics Baylor College of Medicine & Texas Children’s Hospital; 2. Elise G. Austin, MS, GC, Department of Molecular & Human Genetics Baylor College of Medicine & Texas Children’s Hospital; 3. Ingrid A. Holm, MD, MPH, Divisions of Genetics and Endocrinology Children’s Hospital Boston; 4. David A. Diamond, MD, Children’s Hospital Boston Boston Genomics Management Service

- Define disorders of sex development (DSD) and review strategies to sensibly counsel individuals with DSD
- Examine diagnostic complications and treatment options of DSD; illustrate the importance of a multidisciplinary, patient-centered approach to care.
- Identify ethical and psychosocial issues associated with gender assignment.

Submitted/Sponsored by the Pediatric SIG

102 Surgical Management for Inherited Cancer Syndromes: Understanding the Options and Effects on Quality of Life

0.50 CEU

1. Michael A. Howard, MD, NorthShore University Health System; 2. Sarah Y. Boostrom, MD, The Mayo Clinic; 3. Jack Basil, MD, TriHealth - Tristate Gynecologic Oncology; 4. Sam S. Yoon, MD, Massachusetts General Hospital Cancer Center; 5. Pardeep Kaurah, MSc, BC Cancer Agency

- Review prophylactic surgical options (including reconstructive techniques) for common inherited cancer predisposition syndromes (e.g. HBOC, Lynch, FAP, HDGC, etc.), including technical aspects of each surgery.
- Describe clinical outcomes and risk reduction achieved through prophylactic surgery.
- Examine quality of life outcome data for the various surgeries as it pertains to high-risk populations.

Submitted/Sponsored by the Cancer SIG

103 Measuring Patient Outcomes of Genetic Counseling: Why It’s Important, How to Do it, and What Outcomes to Assess

0.50 CEU

1. Jehannine C. Austin, CGC/CCGC, PhD, University of British Columbia; 2. Barbara B. Biesecker, MS, CGC, PhD, NHGRI; 3. Gillian Hooker, PhD, ScM, CGC, NHGRI; 4. Catriona Hippman, MSc, CGC, BC Women’s Hospital & Health Centre

- Discuss the importance of randomized controlled trials in relation to rigorously evaluating the effects of genetic counseling on client outcomes.
- Identify gaps in the existing literature relating to the client outcomes of genetic counseling in different contexts.
- Develop ideas for how to evaluate client outcomes of genetic counseling in different contexts.

Submitted by the Research SIG and JEMF Advisory Group

Sponsored by the JEMF Advisory Group

104 The Impact of NextGen Sequencing of Cell-Free DNA on Prenatal Genetic Counseling

0.50 CEU

1. Edward Kloza, MS, CGC, Division of Medical Screening and Special Testing Department of Pathology and Laboratory Medicine, Women & Infants’ Hospital; 2. Glenn Palomaki, PhD, Division of Medical Screening and Special Testing Department of Pathology and Laboratory Medicine, Women & Infants’ Hospital; 3. Margaret Piper, PhD, MPH, Blue Cross Blue Shield Association Technology Evaluation Center; 4. Stephanie Dukhovny, MD, Brigham and Women’s Hospital; 5. Brian Skotko, MD, Massachusetts General Hospital - Division of Genetics; 6. Diana Bianchi, MD, Tufts University School of Medicine

- Identify the challenges posed to third party payers, primary prenatal care providers, and maternal-fetal medicine specialists by the expansion of cfDNA technology.
- Determine whether next-gen prenatal testing influences genetic counselors’ perceptions of individuals with Down syndrome and other trisomies.
- Evaluate the potential role of next-gen technology in prenatal testing for sex aneuploidies, single gene disorders and pregnancy complications.

Submitted/Sponsored by the Prenatal SIG

105 Epigenetics: Why DNA Sequence Isn’t Everything

0.50 CEU

1. J. Cecelia Bellcross, PhD, MS, CGC, Emory University School of Medicine; 2. Bradford Coffee, PhD, Emory University School of Medicine; 3. Rosanna Weksberg, MD, PhD, The Hospital for Sick Children; 4. Emily Eidelberg, MS, CGC, NCHPES; 5. Kate Reed, MPH, ScM, CGC, NCHPES; 6. Angela Ting, PhD, Genomic Medicine Institute (NE50); 7. Scott Weissman, MS, CGC, NorthShore University Health System; 8. Robert A. Waterland, MD, Drps. of Pediatrics and Molecular & Human Genetics at Baylor College of Medicine

- Describe the epigenome’s role in human development and disease.
- Recognize the testing techniques available for epigenetic assessment in research and clinical practice.
- Apply knowledge of epigenetics to patient care for risk assessment, diagnosis and management.

Submitted by the Personalized Medicine SIG and Public Health SIG

Sponsored by the Personalized Medicine SIG

106 Universal Genetic Counseling Issues Viewed Through a Cardiovascular Lens

0.50 CEU

1. Christina M. Rigelsky, MS, CGC, Cleveland Clinic; 2. Ana Morales, MS, CGC, The Ohio State University; 3. Peggy Crawford, PhD, University of Cincinnati, Department of Neurology; 4. Sonia Suter, MS, JD, George Washington University; 5. Brittan Sutphin, Sudden Arrhythmia Death Syndromes Foundation; 6. Heather MacLeod, MS, CGC, Informed Medical Decisions, Inc.

- Identify best practices to communicate difficult information to children and overcome family communication barriers.
- Assess a family history of heart attack in the pedigree and learn appropriate follow-up questions to help determine different etiologies of this common pedigree finding.
- Recognize important issues for genetic counselors to consider with respect to postmortem genetic testing.

Submitted/Sponsored by the Cardiovascular SIG

Janus Series

3:45 pm – 4:15 pm

107 Practical Guidelines for Managing Patients With The 22q11.2 Deletion Syndrome

0.05 CEU

1. Donna M. McDonald-McGinn, MS, CGC, The Children’s Hospital of Philadelphia

- Recognize the current best scope of practice specific to The 22q11.2 Deletion Syndrome, including all aspects of genetic counseling.
- Incorporate the published Practical Guidelines for Managing Patients With The 22q11.2 Deletion Syndrome into everyday best practice and understand how these apply to individuals with atypical nested deletions and 22q11.2 duplications.
- Recognize the importance of experienced coordinated team care for individuals with The 22q11.2 Deletion Syndrome and define the purpose and outcomes to date of The International 22q11.2 Deletion Syndrome Consortium.

4:15 pm – 4:45 pm

108 Complexities of Hereditary Pancreatitis: Clinical Review and Genetic Counseling Implications for Your Practice

0.05 CEU

1. Sheila Solomon, MS, CGC, University of Pittsburgh

- Provide a comprehensive clinical and genetic review of hereditary pancreatitis.
- Evaluate the multi-factorial data associated with a clinical diagnosis of pancreatitis in patients and their at-risk relatives.
- Explain the complexities of genetic testing on predicting phenotype and recurrence risk along with the associated psychosocial/genetic counseling issues.

Submitted/Sponsored by the Cancer SIG
Distinguish among the three forms of VLCAD deficiency, including
Identify key components of genetic counseling for psychiatric illnesses and
Define normal brain formation, the basis of structural abnormalities seen on
Determine the positive or negative predictive value and clinical significance of
Recognize similarities/differences between the major NIPT studies published
Recognize the benefit of leveraging research results to enhance clinical
Recognize the value of early identification of patients with rare disorders
Summarize the status, successes and pitfalls in using traditional gene
Identify key points for selecting a tumor for MSI/IHC testing.
Review next generation sequencing and CLIA-approved whole exome
List reasons why NIPT should currently be offered to all pregnant women.
Examine the association of a woman having an infant with a congenital
Evaluate evidence from the first RCT of psychiatric genetic counseling,
Explain the various experimental therapeutic options for patients and have
resources for referral of patients to study sites.
Recognize the value of early identification of patients with rare disorders
in order to develop long term follow up programs like the Inborn Errors of Metabolism Collaborative, to clarify natural history and contribute to
development of new therapies and management practices.
Submitted/Sponsored by the Metabolism/Lysosomal Storage Disorders SIG

Best Abstract Awards

5:30 pm – 5:45 pm
Beth Fine Kaplan Best Student Abstract Award
110 Exploring the Relationship Between Diagnoses of Congenital Anomalies or Genetic Conditions and Postpartum Depression: A Retrospective Study
0.025 CEU
1. Meagan F. Wiesenhart, MS, The University of Alabama at Birmingham
   - Examine the association of a woman having an infant with a congenital anomaly and/or specific genetic diagnosis and experiencing postpartum depression.
   - Consider utilization of the Edinburgh Postnatal Depression Scale as a method of screening for postpartum depression in genetic counseling sessions.
   - Recognize areas of genetic counseling practice that may include postpartum depression anticipatory guidance and/or screening as well as genetic counselors’ suitability for these roles.

5:45 pm – 6:00 pm
Best Full Member Abstract Award
111 Genetic Counseling for Individuals with Serious Mental Illnesses: The First, and Only, Randomized Controlled Trial
0.025 CEU
1. Catriona Hippman, MSc, CGC, BC Women’s Hospital & Health Centre
   - Identify key components of genetic counseling for psychiatric illnesses and recognize the similarities and differences between genetic counseling for psychiatric illnesses as compared to other illnesses.
   - Evaluate evidence from the first RCT of psychiatric genetic counseling, including the impact of genetic counseling on the outcome measures: risk perception, knowledge, internalized stigma, and perceived control over illness.
   - Recognize the benefit of leveraging research results to enhance clinical practice and expand service delivery.

Thursday, October 25

Sponsored Breakfast Session
7:00 am – 7:45 am
201 Is Noninvasive Prenatal Testing Ready For All Women? The Great Debate
0.05 CEU
1. Christina Coffeen, MS, CGC; 2. Patricia Devers, MS, CGC; 3. Amy Swanson, MS, CGC
   - Recognize similarities/differences between the major NIPT studies published to date.
   - List reasons why NIPT should currently be offered to all pregnant women.

Identify reasons why NIPT should not necessarily be offered to all pregnant
women at this time.
Sponsored by Verinata Health, Inc.

Educational Breakout Sessions

8:00 am – 10:00 am
202 Pan-ethnic Expanded Carrier Screening
0.20 CEU
   - Describe the experience of pan-ethnic, expanded carrier screening in the preconception and prenatal setting.
   - Review current allele frequency data on testing a nationwide, multi-ethnic population for many recessive diseases.
   - Discuss established criteria and public health precedents in reference to pan-ethnic carrier screening.
Submitted/Sponsored by the Prenatal SIG

203 Dissecting the Utility of MSI/IHC on Colon Polyps and Extracolonic Cancers
0.20 CEU
1. Elena Stoffel, MD, MPH, University of Michigan Health System; 2. Russell Broadus, MD, PhD, The University of Texas: MD Anderson; 3. Sarah Kerr, MD, Mayo Clinic; 4. Maegan Roberts, MS, CGC, Mayo Clinic
   - Determine the positive or negative predictive value and clinical significance of MSI/IHC testing on endometrial and ovarian tumors, sebaceous neoplasms and colorectal polyps.
   - Discuss the utility of MSI/IHC testing on gynecologic tumors based on histologic subtype.
   - Identify key points for selecting a tumor for MSI/IHC testing.
Submitted/Sponsored by the Cancer SIG

204 Building a Brain: Understanding and Researching the Genetics of Brain Development and Function
0.20 CEU
1. A. James Barkovich, MD, University of California San Francisco; 2. Christopher Walsh, MD, PhD, Children’s Hospital Boston; 3. Annapurna Poduri, MD, MGH, Boston Children’s Hospital; 4. Bernard Chang, MD, Harvard Medical School/Beth Israel Deaconess Medical Center
   - Define normal brain formation, the basis of structural abnormalities seen on brain imaging and the spectrum of normal.
   - Review the genetic basis of various congenital brain anomalies and seizure conditions.
   - Summarize the status, successes and pitfalls in using traditional gene analysis and whole genome and exome technologies in diagnosing and researching brain-based anomalies.

205 The Future is Now: The Impact of Next Generation Sequencing as Applied to Whole Exome and Whole Genome Sequencing on the Diagnostic Laboratory and Clinical Practice
0.20 CEU
1. Monica Giovanni, MS, CGC, Brigham and Women’s Hospital; 2. Shami Bale, PhD, FACHE, GeneDx; 3. Michael Murray, MD, Brigham and Women’s Hospital
   - Review next generation sequencing and CLIA-approved whole exome testing to provide a basic understanding of the technology and the testing laboratory’s processes for analyzing and filtering genetic variants.
   - Describe how genome-level data can be used to identify actionable variants and the impact on patients’ test results.
   - Discuss how physicians and genetic counselors approach and apply whole exome/genome sequencing tests in the clinic including pre and post-test considerations.
Submitted/Sponsored by the Personalized Medicine SIG
Thursday, October 25 (Continued)

Plenary Session
10:45 am – 12:15 pm

206 The Clinical Doctorate
0.15 CEU
1. Ann Walker, MA, LCGC, Past President ABGC and NSGC, University of California-Irvine; 2. Brenda Finucane, MS, CGC, President, NSGC; 3. Catherine Reiser, MS, CGC, President, Association of Genetic Counseling Program Directors, University of Wisconsin-Madison; 4. Robin Grubs, PhD, CGC, Past President ABGC, University of Pittsburgh
Distinguish between the PhD, the entry level CD and the Advanced Practice CD as distinct academic pursuits.
List a potential benefit and a potential disadvantage of a Clinical Doctorate for Genetic Counselors from each of the following perspectives: professional, educational and accreditation/credentialing.
Identify and prioritize factors that influence opinions about the possible development of a Clinical Doctorate.
Submitted by the Association of Genetic Counseling Program Directors

207 Early Experiences in Clinical Whole Exome Sequencing
0.10 CEU
1. Alicia Braxton, MS, CGC; 2. Elise Austin, MS, CGC; 3. Gayle Patel, MS, CGC; 4. Sandra Danielek, MS, CGC
Discuss the history, methodology, strengths, and limitations of whole-exome sequencing (WES).
Review the ideal candidates for WES and points to consider in the consent process for testing.
Illustrate results a provider will receive from WES.
Sponsored by Baylor College of Medicine

Educational Breakout Sessions
2:15 pm – 4:15 pm

208 The New Frontier: A Clinical Trial of In Utero Stem Cell Transplantation for Sickle Cell Disease
0.20 CEU
Describe the rationale and experimental support for IUHCT for the treatment of genetic disease.
Compare and contrast potential risks and benefits in utero stem cell transplantation for sickle cell disease to postnatal bone marrow transplantation.
Incorporate knowledge gained into prenatal genetic counseling practice.

209 Beyond Risk Assessment: Novel Application of Whole Genome Technologies to Personalize Oncology Treatment
0.20 CEU
1. Victoria Raymond, MS, CGC, University of Michigan; 2. Scott Kim, PhD, MD, Department of Psychiatry and Center for Bioethics and Social Sciences in Medicine, University of Michigan; 3. Jessica Everett, MS, CGC, University of Michigan
Describe the current and future approaches to genome-based personalized oncology treatment.
Recognize the oncologic, genomic and psychosocial factors important for care collaborations in personalized oncology treatment.
Identify unique roles for genetic counselors in multidisciplinary personalized oncology treatment programs.
Submitted/Sponsored by the Personalized Medicine SIG and Cancer SIG

210 A Hearing Aid for Genetic Counselors: The Full Picture of Hereditary Hearing Loss
0.20 CEU
1. Margaret Kenna, MD, MPH, Children’s Hospital Boston Department of Otolaryngology and Communication Enhancement; 2. Heidi Rehm, PhD, FACMG, Partners Healthcare Center for Personalized Genomic Medicine; 3. Katherine A. Lafferty, MS, CGC, PCCPGM Laboratory for Molecular Medicine; 4. Mark Dunning, The Coalition of Usher Syndrome Research
Summarize the current clinical and genetic aspects of hearing loss and outline the future directions of this field.
Communicate the many components, both clinical and technical, that are involved in determining the etiology of hearing loss including, recognizing the benefits and limitations to genetic testing, testing strategies and subsequent impacts on patient care.
Illustrate the psychosocial implications of hearing loss on a patient and their family and describe available support and resources using examples from an experienced counselor in the specialty of hearing loss and a parent advocate story.

211 Finding the Teacher Within: Working More Effectively with Patients, Peers and Pupils
1. Janet Mulliner, EdD, New York University; 2. Leslie Cohen, MS, CGC, University Hospitals Case Medical Center - Center for Human Genetics; 3. Kelly East, MS, CGC, Hudson Alpha Institute for Biotechnology
Identify key concepts of adult learning theory, including experiential learning, collaborative learning and the power of stories in learning.
Apply the concepts of adult learning theory to the day-to-day interaction of genetic counselors with patients, healthcare professionals and students.
Recognize the needs of the NSGC membership for additional resources on educational topics, as well as identify resources that are currently available.
Submitted/Sponsored by the Education SIG

Plenary Session
4:30 pm – 5:15 pm

212 Clinical Genetic Resources at NCBI
0.075 CEU
1. Brandi L. Kattman, MS, CGC, NCBI/NLM/NIH; 2. Adriana J. Malheiro, MS, NCBI/NLM/NIH
Discover how to become a power user of the GTR with NCBI and other navigation tips.
Demonstrate how to find a test by a variant, and identify the variant’s clinical significance.
List at least four databases at NCBI of use to genetics professionals.

5:15 pm – 6:00 pm

213 Running with the Trait: Ethical and Societal Implications of Mandatory Testing of Athletes for Sickle Cell Trait
0.075 CEU
1. Charmaine Royal, PhD, MS, Duke University, Duke Institute for Genome Sciences & Policy
Describe the historical context of sickle cell screening and need for a socially responsible athletic screening program.
Identify areas of knowledge among athletes and athletic personnel that need to be enhanced to ensure informed consent and ultimate safety of the student-athlete.
Demonstrate ways genetic counselors can use their skills to meet the needs of such screening programs in their area.
Submitted by the Diversity Subcommittee
Identify the relevance of these services to genetic counselors.

Review current literature on psychosocial outcomes and medical decision-making.

Compare and contrast published data on various NIPD models.

Recognize important aspects of imaging evaluations that help define genetic counseling services and progress on these efforts.

Discover attitudes of providers and patients regarding non-invasive testing and how they are applying testing in their clinical practice.

Submit/Submitted by Boulder Abortion Clinic, P.C.

Friday, October 26

Sponsored Breakfast Session

7:00 am – 7:45 am
1. Brynn Levy, MSc, PhD, FACMG, CGC, Columbia University Medical Center
   - Compare and contrast technologies for NIPD detection of chromosome abnormalities (past and present).
   - Describe the complexities involved in isolating the fetal genome from maternal blood.
   - Discuss the scope of clinical disorders detectable and implications for clinical practice.

Submitted/Submitted by the Prenatal SIG

Plenary Sessions

8:00 am – 9:00 am
1. John Richardson, Government Relations Director, NSGC; 2. Joy Larsen, MS, CGC, Humphrey Cancer Center; 3. Wendy Uhlmann, MS, CGC, The University of Michigan
   - Discuss the current status of NSGC’s federal advocacy efforts to obtain reimbursement for services performed by genetic counselors.
   - Review the progress of NSGC’s state licensure efforts.
   - Identify strategies NSGC is using in approaching payers to cover and promote genetic counseling services and progress on these efforts.
   - Outline a leadership role for genetic counselors in promoting an interdisciplinary framework for integrating new genomic tests into patient care.

9:00 am – 9:45 am
1. Lee Shulman, MD, FACOG, FACMG, Department of Obstetrics & Gynecology, Feinberg School of Medicine, Northwestern University; 2. Christin Coffeen, MS, CGC, Venitra Health, Inc; 3. Annette Batley, MS, Ariosa Diagnostics; 4. Melissa Savage, MS, CGC, Natera; 5. Jennifer Hoskovec, MS, CGC, University of Texas Houston Medical School
   - Compare and contrast published data on various NIPD models.
   - Identify the benefits and limitations of non-invasive testing for aneuploidy as well as possible future applications of non-invasive technology.
   - Discover attitudes of providers and patients regarding non-invasive testing and how they are applying testing in their clinical practice.

Submit/Submitted by Integrated Genetics

Sponsored Evening Session

7:30 pm – 9:00 pm
1. Warren M. Henn, MD, MPH, PhD
   - Identify the relevance of these services to genetic counselors.
   - Identify purpose, basic principles and components of clinical practice including grief support.
   - Identify the basic operative procedures and clinical results of this care.

Submit/Submitted by Boulder Abortion Clinic, P.C.

Sponsored by Integrated Genetics

Educational Breakout Sessions

10:00 am – 12:00 pm
304 Merging into Clinical Practice: Updates in Non-invasive Prenatal Testing
   0.20 CEU
   1. Lee Shulman, MD, FACOG, FACMG, Department of Obstetrics & Gynecology, Feinberg School of Medicine, Northwestern University; 2. Christin Coffeen, MS, CGC, Venitra Health, Inc; 3. Annette Batley, MS, Ariosa Diagnostics; 4. Melissa Savage, MS, CGC, Natera; 5. Jennifer Hoskovec, MS, CGC, University of Texas Houston Medical School
   - Compare and contrast published data on various NIPD models.
   - Identify the benefits and limitations of non-invasive testing for aneuploidy as well as possible future applications of non-invasive technology.
   - Discover attitudes of providers and patients regarding non-invasive testing and how they are applying testing in their clinical practice.

Submit/Submitted by the Prenatal SIG

305 Now What am I Supposed to Tell My Fiancé? Psychosocial and Behavioral Outcomes for Unaffected Women with a BRCA Mutation
   0.20 CEU
   1. Lindsey M. Hoskins, PhD, National Cancer Institute; 2. Andrea Patenaude, PhD, Dana-Farber Cancer Institute; 3. Adam Buchanan, MS, MPH, CGC, Duke University Medical Center; 4. Bright Pink Panel
   - Review current literature on psychosocial outcomes and medical decision-making in unaffected women with a BRCA mutation.
   - Report preliminary data on adherence to current risk management recommendations among unaffected women with a BRCA mutation.
   - Report first-person narratives of ways in which having a BRCA mutation has influenced young unaffected women’s medical and psychosocial decision-making.

Submit/Submitted by the Cancer SIG

306 Genetic Aortopathies: An Explosion of Genetic Knowledge
   0.20 CEU
   1. Christina M. Rigelsky, MS, CGC, Cleveland Clinic; 2. Patricia Arscott, MS, CGC, University of Michigan; 3. Dianna Milczewski, MD, PhD, University of Texas Medical School at Houston
   - Identify the genes associated with aortic disease and appreciate the spectrum of clinical findings associated with genetic aortic disease.
   - Recognize important aspects of imaging evaluations that help define genetic arterial disease.
   - Describe the role of new technologies in gene discovery for aortic diseases.

Submit/Submitted by the Cardiovascular SIG

307 Pharmacogenetics: Update on the Field and Roles for Genetic Counselors
   0.20 CEU
   1. Howard McLeod, PharmD, University of North Carolina; 2. Susanne Haga, PhD, Duke Institute for Genome Sciences & Policy; 3. Amy C. Sturm, MS, CGC, The Ohio State University Medical Center; 4. Kevin Sweet, MS, CGC, The Ohio State University Medical Center
   - Gather an understanding of the current status of the field of pharmacogenetics including basic principles as well as the clinical potential and use particularly in the areas of cardiology, oncology, neurology and psychiatry.
   - Recognize ethical and policy issues related to the delivery of pharmacogenetics including interpretation and communication of results as well as data storage and management.
   - Explore current and potential professional roles for genetic counselors in the establishment and support of pharmacogenetic programs.

Submit/Submitted by the Personalized Medicine SIG
Friday, October 26 (Continued)

Sponsored Lunch Session
12:15 pm – 1:45 pm
206 Hereditary Cancer Panels: Review of Initial Results and Discussion about Counseling for Next-Generation Tests
1. Steven Kalies, MS, CGC, Ambry Genetics; 2. Aaron Stuanelk, MS, CGC, Ambry Genetics; 3. Anu Chittenden, MS, LGC, Dana Farber Cancer Institute; 4. Scott Weissman, MS, CGC, NorthShore University HealthSystem; 5. Kory Jasperson, MS, CGC, Huntsman Cancer Institute; 6. Heather Hampel, MS, CGC, The Ohio State University; 7. Megan Myers, MS, CGC, UCSF Cancer Risk Program
- Review of preliminary cancer panel data: mutation and variant rates, insurance coverage and ordering clinician demographics.
- Describe clinicians’ experiences ordering and counseling for hereditary cancer panels, regardless of testing laboratory.
- Evaluate the utility and appropriateness of a next-generation panel testing approach in various clinical scenarios.
- Discuss the current and future roles of next-generation panels in hereditary cancer testing.

Sponsored by Ambry Genetics

5:30 pm – 7:00 pm
Dr. Beverly Rollnick Memorial Lecture
313 Part 1: That’s Just Crazy Talk: A Play and Discussion
0.15 CEU
1. Victoria Maxwell, BFA/BPP, Crazy for Life Co.
- Illustrate symptoms of mania, depression, psychosis and anxiety.
- Describe various experiences and consequences of self-stigma and external stigma.
- Improve skills of empathy and insight into mental illness, treatment and recovery.
- Explore the effectiveness of humor as a recovery tool.

313 Part 2: Research Evaluation of a Play as a Stigma-Reduction Intervention
1. Sagar V. Pankh, MD, FRCP, University Health Network Director of Continuing Mental Health Education, University of Toronto
- Clarify the role of drama as a tool for stigma reduction.
- Identify key measures of stigma measurement in mental health.
- Demonstrate successful stigma reduction through use of a play.

Sponsored Evening Session
7:15 pm – 8:45 pm
314 When More Isn’t Better...Genetic Testing from a Legal Perspective
1. Phil Duffy, Esq.
- Recognize the importance of genetic screening.
- Recognize the challenges of over-utilization.
- Recognize the ideal mix of clinically appropriate and standard of care.

Sponsored by Quest Diagnostics

Saturday, October 27

Sponsored Breakfast Session
7:00 am – 7:45 am
401 When Bigger is Better: Multi-gene Testing Panels for Genetically Heterogeneous Disorders
0.05 CEU
1. Chris Lauricella, MS, CGC; 2. Elizabeth Butler, MS, CGC
- Recognize the benefits and limitations of multi-gene testing panels for genetically heterogeneous disorders.
- Identify patients who can benefit from genetic testing using multi-gene panels for severe combined immunodeficiency (SCID) and epilepsy.

Sponsored by GeneDx

Plenary Sessions
8:00 am – 9:00 am

Late-breaking Plenary Session
402 Targeted Pharmaceuticals for Neurodevelopmental Disorders
0.10 CEU
1. Paul P. Wang, MD, Seaside Therapeutics; 2. Kira A. Dies, ScM, CGC, Boston Children’s Hospital
- Describe the “targeted pharmacotherapy” research approach for neurodevelopmental disorders.
- Identify potential drug targets for the treatment of Fragile X Syndrome.
- Define the manifestations of Tuberous Sclerosis Complex that Rapamycin may affect.

9:30 am – 10:30 am
403 Jane Engelberg Memorial Fellowship (JEMF) Presentation
0.10 CEU
1. Kevin Sweet, MS, CGC, The Ohio State University Medical Center; 2. Dawn C. Allain, MS, CGC, The Ohio State University Medical Center; 3. Kate P. Swayne-Carson, MS, CGC, The Ohio State University Medical Center, Clinical Cancer Genetics; 4. Sara Fitzgerald-Butt, MS, CGC, The Research Institute at Nationwide Children’s Hospital
- Describe the purpose and mission of the Jane Engelberg Memorial Fellowship.
- Outline new resources and CEU opportunities for genetic counselors through JEMF and NSGC to enhance their teaching and counseling skills.
- Discover the findings of original research and provide discussion on the value of genetic counselors in the genetic testing process for Hereditary Breast Ovarian Cancer.

Submitted by the JEMF Advisory Group

Educational Breakout Sessions
10:30 am – 12:30 pm
404 Counseling Difficulties and Ethical Concerns in an Uncertain Prenatal Diagnosis
0.20 CEU
1. Jamie Chance, MS, CGC, Regional Perinatal Center, Odessa Regional Medical Center; 2. Curtis R. Coughlin II, MS, MBie, University of Colorado; Children’s Hospital of Colorado; 3. Holly H. Zimmerman, MS, CGC, University of Mississippi Medical Center; 4. Martha Dudek, MS, CGC, Vanderbilt University; 5. Rebecca Carter, MS, CGC, University of Texas Health Science Center
- Describe and review counseling techniques and management options in pregnancies that have a likely, but not an absolutely, lethal diagnosis.
- Illustrate how to present the option of comfort care: tips, do’s and don’ts.
- Discuss the controversy and ethical implications in management of a pregnancy with a lethal or a potentially lethal diagnosis.

Submitted/Sponsored by the Prenatal SIG and Ethics Advisory Group

405 Familial Pancreatic Cancer: From Evaluation to Endoscopy
0.20 CEU
- Describe the currently known inherited cancer syndromes that predispose to pancreatic cancer, both adenocarcinoma and neuroendocrine, and the clinical utility of genetic testing for each.
- Recognize ongoing new gene discovery efforts and how to use those discoveries in patient care.
- Identify the benefits and limitations of currently available pancreatic screening methods, and how to manage individuals and families with hereditary pancreatic cancer.

Submitted/Sponsored by the Cancer SIG
AEC Session Objectives

Saturday, October 27 (Continued)

0.20 CEU
1. Laura Hercher, MS, CGC, Sarah Lawrence College; 2. Barbara A. Bernhardt, MS, CGC, University of Pennsylvania; 3. Regan Weith, MS, CGC, Children’s Hospital of Wisconsin; 4. Amy White, MS, CGC, Children’s Hospital of Wisconsin; 5. Benjamin Berkman, JD, MPH, National Human Genome Research Institute, National Institutes of Health; 6. Flavia M. Facio, MS, CGC, National Human Genome Research Institute, National Institutes of Health

- Outline the application of whole genome and exome sequencing technologies in the pediatric setting and describe the current challenges in obtaining informed consent and returning results.
- Report the early experiences of genetic counselors working in this novel setting and outline the complexities of providing genetic counseling for whole genome and exome sequencing through the use of case examples.
- Describe broad ethical guidance and recommendations on how to approach issues related to informed consent and return of results in the pediatric population, specifically in cases where minors are found to carry variants that are known or suspected to cause or predispose to adult-onset conditions.

Submitted by the Public Policy Committee and Ethics Advisory Group

407 Hints from the Experts: Job Interviewing Skills
0.20 CEU
1. Mary Jarvis Ahrens, MS, CGC, University of Minnesota Medical Center, Fairview; 2. Elizabeth Balkite, MS, Sarah Lawrence College; 3. Debra Collins, MS, CGC, KUMC; 4. Elizabeth Gettig, MS, CGC, University of Pittsburgh; 5. Teresa Kruisselbrink, MS, CGC, Mayo Medical Center; 6. Bonnie S. LeRoy, MS, CGC, University of Minnesota; 7. Caroline Lieber, MS, CGC, Sarah Lawrence College; 8. Maureen E. Smith, MS, CGC, Center for Genetic Medicine, 9. Wendy Uhlmann, MS, CGC, Division of Molecular Medicine and Genetics, Department of Internal Medicine University of Michigan; 10. LuAnn Weik, MS, CGC, Children’s Hospital of Wisconsin; 11. Vivian Weinblatt, MS, CGC, Integrated Genetics

- Recognize challenging interview questions and learn how to answer them appropriately during a job interview.
- Determine the critical factors for evaluation of applicants by genetic counselors in a position to hire them.
- Review and teach genetic counseling students effective communication skills that the presenters have learned in their jobs and in interviewing genetic counselors for positions at their institutions.

Sponsored Lunch Session

12:30 pm – 2:00 pm

408 Using Cost Effectiveness Modeling to Demonstrate the Value of Genetic Services
0.10 CEU
1. David Stenehjem, PharmD

- Outline the definitions and terms used in cost effectiveness modeling studies and health economics and why they are valuable measures of healthcare outcomes.
- Define how cost effectiveness modeling studies are done, how the models work and how they should be interpreted in the context of a practicing healthcare provider.
- Discuss recent cost effectiveness modeling studies in genetics, highlighting how they have been informative to testing guidelines, medical policy and payer coverage.

Sponsored by Myriad Genetic Laboratories, Inc.
Harmony™
PRENATAL TEST

An advanced blood test to detect common fetal trisomies anytime after 10 weeks gestation and later

The Harmony Prenatal Test analyzes the relative number of chromosomes in maternal blood to provide an objective individualized result with high sensitivity and specificity.

- Non-Invasive
- Simple
- Accurate
- Affordable

To learn more about the Harmony Prenatal Test, please visit www.ariosadx.com

Ariosa, Harmony and Harmony Prenatal Test are trademarks of Ariosa Diagnostics, Inc. © 2012 Ariosa Diagnostics, Inc. All rights reserved.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 pm –</td>
<td>Genetic Education Materials for School Success (GEMSS): A Guide for the Classroom for Children with Genetic Conditions</td>
<td>C. Giummo</td>
</tr>
<tr>
<td>2:15 pm –</td>
<td>Deletion Mutations Bordering Exon 44 of the DMD Gene: The CINRG Experience</td>
<td>N. Mans</td>
</tr>
<tr>
<td>2:15 pm –</td>
<td>Implementation of Institutional MSI and IHC Testing for Diagnosis of Lynch Syndrome: The Cleveland Clinic Experience</td>
<td>B. Leach</td>
</tr>
<tr>
<td>2:15 pm –</td>
<td>Consumer Preferences for the Reporting of Genetic Variants of Uncertain Significance</td>
<td>N. Smith</td>
</tr>
<tr>
<td>2:15 pm –</td>
<td>The Impact of Supervision Training on Genetic Counselors’ Supervisory Identity Development</td>
<td>K. Lewis</td>
</tr>
<tr>
<td>2:30 pm –</td>
<td>Mosaicism Due to Reversion: A Report of a Rare 20pter-p13 Deletion</td>
<td>M. Martin</td>
</tr>
<tr>
<td>2:30 pm –</td>
<td>Universal Lynch Syndrome Screening Result Notification</td>
<td>H. Hampel</td>
</tr>
<tr>
<td>2:30 pm –</td>
<td>Role of Numeracy and Genetic Literacy in the Desire to Receive Genetic Risk Information</td>
<td>I. Yurkiewicz</td>
</tr>
<tr>
<td>2:30 pm –</td>
<td>The Pregnancy and Health Profile Pilot Project: Evaluating the Patient Satisfaction and Usability of a Novel Prenatal Family History and Genetic Screening Tool</td>
<td>E. Edelman</td>
</tr>
<tr>
<td>2:45 pm –</td>
<td>Gaucher Disease Type 3 Due to Chromosome 1 Uniparental Dismy</td>
<td>C. Brasington</td>
</tr>
<tr>
<td>2:45 pm –</td>
<td>Age of Onset and Predictors of Medullary Thyroid Cancer in Patients with Lower Risk RET Proto-Oncogene Mutations</td>
<td>T. Rich</td>
</tr>
<tr>
<td>2:45 pm –</td>
<td>Deaf Genetic Testing and Psychological Well-Being</td>
<td>C. Palmer</td>
</tr>
<tr>
<td>2:45 pm –</td>
<td>The New Face of Genetics: A Multimedia Educational Tool</td>
<td>J. Martineau*(Poster)</td>
</tr>
<tr>
<td>3:00 pm –</td>
<td>Integration of Genetic Services into Pediatric Patient Care: A National Survey of Pediatric Primary Care Physicians</td>
<td>W. Uhlmann</td>
</tr>
<tr>
<td>3:00 pm –</td>
<td>Turcot Syndrome: A Case Report of a 15-Year-Old with Diffuse Colon Polyposis and Medulloblastoma</td>
<td>J. Fulbright</td>
</tr>
<tr>
<td>3:15 pm –</td>
<td>Evaluation of Knowledge Regarding Diagnostic Strategies for Genetic Diseases in Select Residents</td>
<td>S. Penney</td>
</tr>
<tr>
<td>3:15 pm –</td>
<td>Evidence for Maternal Mosaicism in OPHN1</td>
<td>A. Schreiber</td>
</tr>
<tr>
<td>3:15 pm –</td>
<td>The Clinical Presentation of an Adult Patient with Biallelic Mutations in PMS2</td>
<td>L. Mar</td>
</tr>
<tr>
<td>3:15 pm –</td>
<td>Accuracy of the BRCAPro Risk Assessment Model in Males Presenting to MD Anderson Cancer Center for BRCA1 and BRCA2 Testing</td>
<td>C. Garby</td>
</tr>
<tr>
<td>3:15 pm –</td>
<td>Development of a Clinical Supervisor Support Program</td>
<td>C. Atzinger</td>
</tr>
<tr>
<td>3:15 pm –</td>
<td>Associations Between Parents’ Psychosocial Outcomes and Their Perception of Providers’ Communication After Newborn Screening Identifies Genetic Carrier Status for Cystic Fibrosis or Sickle Cell Hemoglobinopathy</td>
<td>A. La Pearn</td>
</tr>
<tr>
<td>3:15 pm –</td>
<td>Comprehension and Family Communication of Hereditary Cancer Risk Among African Americans</td>
<td>T. Morgan</td>
</tr>
<tr>
<td>3:15 pm –</td>
<td>Assessment of Individuals with BRCA1 and BRCA2 Large Genomic Rearrangements in High-Risk Breast Cancer and Ovarian Cancer Families</td>
<td>A. G. Arnold</td>
</tr>
</tbody>
</table>
### Saturday, October 27

<table>
<thead>
<tr>
<th>Room 200</th>
<th>Room 302/304/306</th>
<th>Room 210</th>
<th>Room 207</th>
</tr>
</thead>
</table>
| **409 – Counseling/ Psychosocial Issues Papers**  
1. Describe common psychosocial and counseling techniques in genetic counseling sessions.  
2. Discuss patient concerns and quality of life.  

**410 – Pre- and Perinatal Papers**  
1. Discuss the latest developments in prenatal testing and prenatal genetic counseling.  
2. Describe the attitudes and perceptions of patients and providers in the prenatal clinic.  

**411 – Adult Papers**  
1. Discuss genetic conditions seen in adult patients.  
2. Review genetic issues related to common complex diseases.  

**412 – Professional Issues Papers**  
1. Recognize the professional and personal experiences of genetic counselors.  
2. Identify potential future opportunities for the field of genetic counseling. |

| 2:00 pm – 2:15 pm | The Role Of Family Functioning in Promoting Adaptation Among Siblings of Individuals with Duchenne Muscular Dystrophy (MDM)  
B. Pappa | Value of Non-invasive Prenatal Testing in the Third Trimester  
W. DiNonno | Disclosure of Whole Genome Sequencing Findings: Perspectives of Individuals Affected with and Predisposed to Genetic Disease  
K. Bon tempo | Diagnostic Yield of a 180K Array Based Comparative Genomic Hybridization in a Pediatric Population  
J. Kaylor |

| 2:15 pm – 2:30 pm | Importance of Confirmation for Positive Non-invasive Prenatal Testing Results  
V. Cherepakho | Utility of SNP Microarray for Chromosomal Abnormality Analysis in POC by Trimester  
H. Taylor | Utilizing Illness Representations to Improve Family Communication Within A Population At-Risk for Cardiomyopathy  
B. Batte | Creating Professional Development Opportunities in Research for Practicing Genetic Counselors  
M. Myers |

| 2:30 pm – 2:45 pm | Retrospective Study of Little People (LP) Pregnancy: Experiences, Opinions and Utilization of Genetic Counseling Services  
C. Blout | Exploring the Perceptions and the Role of Genetic Counselors in the Emerging Field of Perinatal Palliative Care  
M. Dudek | Comparison of Informed Consent Preferences for Multiplex Genetic Carrier Screening Among a Diverse Population  
A. Reeves | A Strategy to Improve the Quality and Economics of Laboratory Send-outs at Seattle Children's Hospital: The Role of the Laboratory Genetic Counselor  
J. Conta |

| 2:45 pm – 3:00 pm | Parental Attitudes Regarding Newborn Screening for Duchenne Muscular Dystrophy  
K. Buser | Non-vascular Ehlers-Danlos Syndrome and Pregnancy: What are the Risks?  
K. Sondergaard | Phenotypic and Neurocognitive Characterization of Adults with 17p13.3 Microduplication Syndrome  
S. Goldstein | Training Genetic Counselors for the Variety of Roles Available within the Field  
E. Heckaman |

| 3:00 pm – 3:15 pm | Motivations and Characteristics of Families who Adopt Children with Special Needs: A Qualitative Study  
B. Gallinger | Long Term Follow-Up of Morbidity and Quality of Life Associated with Isolated Gastroschisis  
R. Mostafavi | A Collaborative Approach to Integrating Genetics into Healthcare  
A. Trepanier | Expanding the Genetic Counseling Workforce: Program Directors Views on Increasing the Number of Graduates and Factors Influencing the Growth of Graduate Programs  
V. Pan |

| 3:15 pm – 3:30 pm | Genetic Testing in Potential BRCA1/2 Carriers Aged 18 to 25 Years: Decision-making and Impact  
A. Herschner | Prenatal Testing for Noonan Spectrum Disorders in Fetuses with Increased NT and Cystic Hygroma  
E. Kramer | Sickle Cell Trait Testing at NCAA Division 1 Universities: Sports Physicians and Athletic Trainers’ Perspectives  
N. Brown | The Long and Short of Genetic Counseling Summary Letters: A Case-Control Study  
J. Roggenbuck |
Announcing

Enhancements to Myriad’s COLARIS® testing for Lynch syndrome

Complete sequencing and large rearrangement analysis of the PMS2 gene, which now also includes large rearrangement testing for exons 3, 4, and 12-15.

The Myriad Advantage:

• **Genetics Specific Customer Service Support**
  Myriad offers a wide array of customer service support unparalleled to any other diagnostic laboratory, including our newly created Customer Service teams dedicated to the support of our genetics customers.

• **PMS2 Test Development and Validation**
  Myriad employs an extensive automated laboratory testing platform and data analysis system for the PMS2 gene which results in short turn-around-time and a high level of quality.

• **Variant Classification Program (VCP)**
  The VCP includes all of the Lynch syndrome testing available at Myriad, including variants in MLH1, MSH2, MSH6, EPCAM and PMS2.

• **Ordering Process**
  You can request testing in any combination to fit the needs of your patient.

• **Medical Services Support**
  Myriad has over 40 highly trained Medical Specialists to answer clinical or technical questions, review cases and assist in results interpretation.

Visit Myriad at booth #315 for more information
Posters with Authors

Objective:
Describe the most recent research, techniques and approaches in the field of genetic counseling.

214
0.15 CEU

Adult

1 Cholesteryl Ester Storage Disease (CESD): An Under-Recognized Disease of Lysosomal Acid Lipase Deficiency with Liver Dysfunction/Failure and Hyperlipidemia
D. L. Bernstein

2 Liver Disease and Chronic Liver Failure have Complete Penetrance in Cholesteryl Ester Storage Disease, a Form of Lysosomal Acid Lipase Deficiency
D. L. Bernstein

3 Left Ventricular Hypertrophy Aids in Identification of Patients with Aneurysm Osteoarthritic Syndrome Caused by SMAD3 Mutations
D. S. Clements

4 The Iceberg and the Helix: Investigating the Role of Genetic Testing and Genetic Counselors in the Diagnosis and Management of Celiac Disease
V. Duke

5 Factors Influencing Clinician Satisfaction with APOE Genotype Disclosure Counseling Sessions: The REVEAL Study
S. Everhart

6 Prevalence of Premature Ovarian Failure in Women with Tuberous Sclerosis Complex
E. Gabitzsch

7 Differences in Management Recommendations for Adults with Cognitive Disability Based on Genetic Diagnosis Status
L. A. Gress

8 Developing and Validating the Family Members of Individuals with Mental Illness Internalized Stigma (FaMIL-IS) Scale: A New Genetic Counseling Outcome Measure
C. Hippman

9 Interest in Genetic Testing for Complex Diseases: Age-Related Macular Degeneration (AMD) and the Elderly Perspective
M. L. Kluge

10 Huntington Disease: Ten Years After Testing
R. Koff

11 Referral Patterns and Utilization of Clinical Genetic Testing for Patients with Inherited Cardiac Disease
O. Myers

12 Factors Impacting Attendance for Cardiovascular Genetic Counseling after Physician Referral of Hypertrophic Cardiomyopathy Patients
B. Psensky

13 Evaluating the Current Genetic Testing Practices around Huntington Disease
N. Reyes

14 Evaluation of Mutations Causative of Inherited Cardiovascular Disease
E. Smith

15 Implications for the Prevention of Type 2 Diabetes: Investigating the Relationship Between Religiosity, Genetic Explanations for Diabetes and Control Over Diabetes Risk
J. A. Tietjen

16 A Clinical Tool for Classification of Frontotemporal Degeneration Pedigrees
E. McCarty Wood

Cancer

17 Attitudes and Awareness about Insurance Discrimination Among Consumers Seeking Information from a Hereditary Breast and Ovarian Syndrome Advocacy Group
D. C. Allain

18 The Genetic Counseling Experience in a Multidisciplinary Childhood Cancer Survivor Center
K. Armstrong

19 A Contiguous Gene Deletion of 9p21.3 Characterized by NF-like Features, Melanoma, and CNS Tumors
M. J. Baker

20 Do BRCA1 and BRCA2 Positive Women Need Better Follow-up? Gaining Perspective from a Midwest Population
S. A. Cohen

21 Current Lynch Syndrome Screening Practices: A Survey of Genetic Counselors
S. A. Cohen

22 Integration of Family Health History in Clinical Guidelines for Breast, Ovarian, and Colorectal Cancer
A. A. Collier

23 Influence of Cost on Patient Interest in Genetic Testing for Hereditary Colorectal Cancer: Implications for Universal Tumor Screening
D. L. Cragun

24 A Statewide Survey of Practitioners to Assess Recommendations and Clinical Practices Regarding Hereditary Breast and Ovarian Cancer
D. L. Cragun

25 Comparing Male and Female BRCA1/2 Mutation Carriers Communication of their BRCA1/2 Test Results to Family Members
H. J. Dreyfuss

26 Desmoid Tumor as an Extracolonic Manifestation in MYH-associated Polyposis: A Case Report
V. Duke

27 Lost To Follow Up: An Investigation of Individual Reasons For Declining Cancer Genetic Counseling
J. Fan

28 Evaluating the Approach to Unaffected Consultands Presenting to High-Risk Clinical Cancer Genetics Program
S. L. Gustafson

29 Personalized Risk Assessment through Genetic Testing of Uveal Melanoma: Patient Desire, Uses, and Impact
A. Hildebrandt

30 Assessing the Role of the Cancer Genetic Counselor following Disclosure of BRCA1/2 Positive Results
J. Kent

31 Universal Lynch Syndrome Screening Implementation in an Integrated Health-Care Delivery System
M. Morse

32 Early-onset, Bilateral Clear Cell Renal Cancer Associated with Germline Balanced Chromosome Translocation t(3;8)(p14;q24.1) A Case Report
M. S. Niell
Posters

33 Don’t Google It: Perceptions of Internet Use and Social Networking Among Young BRCA1/2 Carriers  
R. Nusbaurm

34 A Comparison Study Evaluating Screening Practices Post Genetic Counseling in Individuals with Lynch Syndrome Versus Individuals with HNPCC  
K. E. Orio

35 Population-based Cancer Genetic Screening in Rural and Underserved Populations in Texas  
L. Robinson

36 The New Look of Lynch Syndrome: Uninformative Genetic Testing  
L. Robinson

37 Attitudes About Predictive MEN1 Genetic Testing in Minors  
K. R. Rock

38 Next Generation Sequencing of 14 Genes Implicated in Hereditary Breast Cancer in the Clinical Setting  
J. D. Siegfried

39 Pancreatic Cancer Risk Perception and Worry in Familial High-Risk Patients Undergoing Endoscopic Ultrasound for Surveillance  
E. L. Silve

40 Genetic Counselors Improve Outcomes for BRCA1/2 Positive Patients  
C. Prochniak

Counseling/Psychosocial Issues

41 Adoption and Family History  
K. A. Calcagno

42 Autism Spectrum Disorder in Multiplex Families: A Qualitative Study of Diagnostic Experiences and Parental Perceptions  
I. Chilton

43 Huntington Disease Living Positive Group: Expanding Services for Gene Positive and At Risk Individuals  
K. J. Delp

44 Patient Decisions for Disclosure of Secondary Findings Identified from Clinical Diagnostic Exome Sequencing  
K. D. F. Gonzalez

45 Every Picture Tells a Story: Effects of Photographic Images on Genetic Counseling and Medical Students’ Perceptions of Genetic Conditions  
J. Holle

46 Knowledge and Attitudes Regarding Genomic Medicine in South Florida’s Hispanic and African American Communities  
K. Czape

47 Coping Mechanisms in Fathers of Children with Mucopolysaccharidoses  
J. Jesiolowski

48 Genetic Counselors’ Views of Consanguineous Couples  
R. E. Kiely

49 Disability Awareness Training and Implications for Current Practice: A Survey of Genetic Counselors  
L. A. Kline

50 A Theory-based Decision Tree for Determining Psychosocial Goals for Genetic Counseling Sessions  
T. Magyari

51 Male Attitudes on Forming and Maintaining Romantic Relationships with Women Who Have BRCA1/2 Mutations  
C. Mauer

52 Discussing the Psychiatric Manifestations of 22q11.2 Deletion Syndrome: An Exploration of Clinical Practice Among Medical Geneticists  
E. M. Morris

53 Understanding the Beliefs of Ashkenazi Jewish Individuals Regarding Cancer Genetic Counseling Services  
R. S. Pearlman

54 Is Worry Associated with Screening for Colon and Breast Cancers?  
J. Quillin

55 Clearing the Air: An Investigation of Genetic Counselors’ Experiences with Patient Anger  
L. Schema

56 Assessing and Addressing Family Member Attitudes and Perceptions of Acute Necrotizing Encephalopathy  
R. J. Sisson

57 Potential Co-occurrence of Amyotrophic Lateral Sclerosis and Huntington Disease: A Family’s Burden of Knowledge and a Genetic Counseling Challenge  
A. L. Smith

58 Perinatal Loss Manifested Through the Lens of the Extended Family Unit  
M. Steeves

59 There’s a Whole Different Way of Working with Adolescents: Interviews with Australian Genetic Counselors about Their Experiences with Adolescent Clients  
C. A. K. Tse

60 Exploring the Nature of Empathy in Genetic Counseling: Components, Functions, and Counselor Behaviors  
E. VandenLangenberg

61 Genetic Counseling for Incomplete Penetrance Mutations in Retinoblastoma  
S. E. Walther

Education

62 Educating Genetic Counseling Graduate Students: Impact of Year of Training, Learning Styles, and Use of Practice-Based Learning on Satisfaction with the Learning Environment  
L. Cohen

63 Genetics/Genomics Competency Center for Education (G2C2)  
M. Doerr

64 Clinical Cancer Genetics Resources requested by Florida-based Healthcare Providers who Offer BRCA1 and BRCA2 Testing  
C. Lewis

65 Supervision Experiences of Genetic Counseling Students with Differing Levels of Trait Anxiety: A Qualitative Investigation.  
I. M. MacFarlane

66 Investigating the Feasibility of a Clinical Doctorate for Genetic Counselors: Managerial and Institutional Support  
R. Mueller

67 Genetic Counselors’ Laboratory Experiences: Perspectives from Recent Graduates  
K. Krepkovich

68 Physicians & GINA: Awareness & Knowledge of Anti-Genetic Discrimination Laws Amongst Obstetrician-Gynecologists & Oncologists  
B. M. Nehorayr

69 Assessing the Integration of Genomic Medicine into Genetic Counseling Training Programs  
J. Profato
Genetic Testing

70 Knowledge, Attitudes and Behaviors of Women in College Towards Alcohol Consumption During Pregnancy
   D. Ratousi

71 Genetic Counselors as Educators: Teaching High School Students about Rare Diseases
   J. Su

72 Genomics Knowledge, Impact and Importance in a Survey of Physicians in British Columbia (BC), Canada
   R. Thomas

73 The Effect of Perceived Increased Risk for Unhealthy Body Shape on the Attitudes and Behaviors of Adolescent Girls: Evaluating an Educational Intervention
   K. Young

74 Assessing Genetics Providers Perspectives of and Experiences with DTC Genetic Testing: Creation of an Educational Module
   A. Bettinelli

75 Mutation Distribution and VUS Rates Among the Five Genes Currently Analyzed in Lynch Syndrome Testing
   A. Bodell

76 Parental Beliefs and Attitudes Towards Testing Children for Hereditary Breast and Ovarian Cancer Genes
   A. Brosseau

77 Comprehensive Molecular Diagnostic Testing Using a Next-Generation Sequencing Panel and Exon-Level Array CGH Identifies Mutations in a Broad Spectrum of Epilepsy Phenotypes
   E. Butler

78 Pathogenic Or Not? Discrepant Classifications Of Genetic Variants Reveal Inherent Challenges In Interpretation Of Genetic Test Results.
   C. Caleshu

79 When the Unexpected Occurs: The Importance of Parental Testing Prior to Predictive Testing
   L. M. Catalano

80 Non-Invasive Prenatal Testing: Views of Genetic Counselors and Implications for the Profession
   M. Clark

81 Genetic Testing for Hypertrophic Cardiomyopathy and Dilated Cardiomyopathy: Identification of Multiple Mutations in a Large Cohort of Patients
   A. Daly

82 Clinical Re-sequencing of Over 410 Genes to Diagnose Mitochondrial Disorders
   J. DaRe

83 Evaluation of Comparative Genomic Hybridization (CGH) and Single Nucleotide Polymorphism (SNP) Array Testing of Products of Conception
   A. Fuller

84 The Practices, Knowledge and Comfort Level of Genetics Professionals’ Counseling for SNP Microarray Results that Suggest Parental Relatedness
   L. Grote

85 Recruiting Diverse Populations for Large-Scale Genomic Studies
   M. Gyure

86 Whole-Exome Sequencing Identifies Novel Risk Variants for Thrombotic Storm
   S. Hahn

87 Genomic Technologies: Effective Integration into Clinical Care
   N. Hoang

88 Informed Consent for Whole-Genome or Whole-Exome Sequencing: Insights from Participants Across the Health Spectrum
   L. Jamal

89 The Next Generation of Cardiomyopathy Testing: Experiences from the First Year
   M. A. Kelly

90 Assessment of Awareness and Opinion of Direct-to-Consumer Genome Testing Among Physicians and Medical Students
   S. Levy

91 The Student Athlete’s Knowledge of Sickle Cell Trait and the Impact of Mandatory Genetic Testing
   N. Lovick

92 Informatics-based Molecular Karyotyping of Products of Conception (POC) with Maternal Cell Contamination (MCC) Detection: Report on 2,381 Consecutive Analyses
   M. Maisenbacher

93 The Implementation and Impact of Student Athlete Sickle Cell Trait Screening: A Survey of California Division I Universities
   L. S. Mar

94 PTEN Mutations in Patients First Tested for Other Hereditary Cancer Syndromes: Would Use of New Risk Assessment Tools Have Reduced Healthcare Costs?
   J. Mester

95 Participant Trust and Preferences in Delivery of Genomic Risk Information for Type 2 Diabetes
   R. Mills

96 Comparison of the Collective Incidence of Diseases in a Multi-disease Carrier Screening Panel to Trisomy 21, 18 and 13: Implications for Screening Recommendations
   K. Ready

97 Poster withdrawn

98 Low-level Mosaicism identified in DNA from Buccal Sample
   M. Sdano

99 Gross Deletions in APC Promoter 1B Account for a Significant Proportion of FAP-causing Mutations: Data from Diagnostic Testing at a Single Clinical Laboratory
   A. J. Stuenkel

100 Variants of Unknown Significance on Long QT and CPVT Test Reports: Reducing Uncertainty
    L. R. Susswein

101 The Student Athlete’s Knowledge and Perceptions of Sickle Cell Trait in Regards to the National Collegiate Athletic Association’s Sickle Cell Trait Testing Regulations
    N. E. Thompson

    J. L. Walsh

103 Parental Attitudes Toward Newborn Screening for Duchenne/Becker Muscular Dystrophy and Spinal Muscular Atrophy
    M. F. Wood
Posters

104 The Right Test Leads to Less Stress: Navigating the Complex and Changing Landscape of Genetic Testing for Fanconi Anemia
H. A. Zierhut

105 Elastin Gene (ELN) Mutations Causing Isolated Supravalvular Aortic Stenosis: A Case Report and Review of the Literature
L. N. Ahles

106 The Clinical Phenotype of Sickle Cell Disease in Nagpur, India: Is it Truly Milder?
A. Arjunan

107 Assessing the Utility of Array CGH as a First-tier Diagnostic Test for Neonates with Congenital Heart Disease
K. K. Bachman

108 Hyperphagia in Children with Smith-Magenis Syndrome: What Should We be Telling Parents?
L. V. Barton

109 Phenotypic Variability in Families with Inherited 16p11.2 Microdeletions
K. Barr

110 Unintentional Diagnosis of Mucolipidosis Type IV by Muscle Biopsy – Unusual but Effective
L. Carey

111 Genetic Complexity in Senior-Loken Syndrome, a Ciliopathy: Report of a Patient with Nephronophthisis, Pigmentary Retinopathy, and Metaphyseal Dysplasia Associated with Multiple Gene Mutations and Microarray Homozygosity
E. N. Chisholm

112 An Interstitial Microdeletion of 9p24.1p23 Due to an Unbalanced Translocation t(5;9) in a Mother and Daughter
S. Cordes

113 Assessing Genetic Risk of Autism Spectrum Disorder in Siblings of Children with ASD
E. J. Couchon

114 A Regulatory Variant in FZD6 Gene Contributes to Nonsyndromic Cleft Lip and Palate (NSCLP)
N. Cvetkovic

115 Parents’ Experiences with Genetics Services for Autism Spectrum Disorders
K. Czape

116 Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1 (GD1): Phase 2 Results After 4 Years of Treatment
K. A. Grinzaud

117 Parental Disclosure of G6PD and Its Relationship to Child Health in a Chinese Population
Y. Guan

118 The Medical Care of Children Born with Ambiguous Genitalia from the Parent Perspective
N. Herrig

119 Gain of Function Abnormality with Phenotype Overlapping Syndromes Due to Autosomal Recessive Mutations in Homeobox Genes
G. A. Jervis

120 A New Form of Spondyloepimetaphyseal Dysplasia (SEMD): Multiple Contributing Genomic Rearrangements Complicate the Interpretation of Inheritance in an as yet Undefined Type of SEMD
K. Langley

121 Perceptions of Hippotherapy by Parents and Their Children with Spinal Muscular Atrophy
D. Lemke

122 8p22.1 Microdeletions and Microduplications - Further Characterization of the Nablus Mask-Like Facial Syndrome Critical Region
M. Mikhaelian

123 Parental Interest in a Genetic Risk Assessment for Autism Spectrum Disorders
V. Narcisa

124 Infantile Hypertrophic Cardiomyopathy and Developmental Delay in a Male with a 14.76Mb Terminal Deletion of 4q34.2 to 4qter and a 10.41Mb Terminal Duplication of 6q25.3 to 6qter
S. E. Parisotto

125 Orthopedic Manifestations and Implications for Individuals with Costello Syndrome
S. Rickard

126 Parental Awareness, Attitudes, and Experiences of Genetic Testing in Autism Spectrum Disorders
A. Rupchock

127 Kabuki Syndrome: Mutation Spectrum of the MLL2 Gene by Sequence and Deletion/Duplication Analysis
A. K. Tanner

128 The Importance of Inclusion of Gene Lists on Microarray Reports: A Case Study
E. Vargal

129 Digenic Inheritance Involving the USH2A and ABCA4 Genes in One Family with Autosomal Recessive Retinitis Pigmentosa
C. Lauricella

Pre- and Perinatal

130 Renal Anomalies, Polyhydramnios and Single Umbilical Artery as Prenatal Clues and Genitourinary Anomalies as Postnatal Clues to the Diagnosis of 22q11.2 Deletion Syndrome
L. Amlie-Wolf

131 Potential Determinants of Anxiety After a Positive Maternal Serum Screen for Trisomy 21
S. Avery Stover

132 Prenatal Genetic Counseling for the In Vitro Fertilization Patient
N. Boxer

133 The Frequency of Chromosome Abnormalities Among Fetuses with an Ultrasound Finding of Skeletal Abnormalities
D. Durand

134 Prenatal Screening and Diagnosis for Down Syndrome: Collaborative Efforts to Educate Providers and Women
C. Feist

135 An Intrachromosomal Insertion Characterized in a Patient After Having One Child with a 17q21.31 Deletion and a Subsequent Child With a Duplication of the Same Region
K. Fritinger

136 The Clinical Spectrum of 9q22.3 Deletion Syndrome
D. Gomez

137 A Novel 9q Interstitial Deletion Associated with the Rare Prenatal Finding of Bilateral Adrenal Prominence
L. M. Haymon

138 The Decision to Continue a Pregnancy Affected by Down Syndrome: Timing of Decision and Satisfaction with Receiving the Diagnosis Prenatally
E. Hurford

139 The Natural History of Pregnancies Diagnosed with Down Syndrome: Developing Counseling and Pregnancy Management Guidelines
C. Kiss
A Model for Providing Patient Education and Care When Offering a Comprehensive Pan-Ethnic Carrier Screen
R. T. Klein

The Impact of Visual Aids on Prenatal Genetic Counseling Session Patient Outcomes
B. L. Knyszek

How Important Is Your Sonographer? Sonographer Variation and Its Effect on Down Syndrome Risk Calculation
D. LaGrave

Let’s Put it to the Test: Using Maternal Urine as a Prenatal Screen for Smith-Lemli-Opitz Syndrome (SLOS)
R. Lobo

Potential Secondary Impacts of Carrier Screening: Exploring Professional Opinions on the Link Between Gaucher Disease Carrier Status and an Increased Lifetime Risk of Parkinson Disease
E. McCarty Wood

Noninvasive Prenatal Testing for Fetal Monosomy X: Clinical and Genetic Counseling Considerations
T. Prosen

The Current Landscape of Prenatal Aneuploidy Screening: Perspectives of Genetic Counselors in the United States
J. L. Silver

Fetal Fragile X Testing Among Premutation Carriers: Influence of Premutation Length and Family History
A. Warner

Cystic Fibrosis Carrier Screening: Current Practices and Challenges in Genetic Counseling
E. J. Wellington

Ten Years After the First Savior Siblings: Parental Experiences Surrounding Preimplantation Genetic Diagnosis
H. A. Zierhut

Whole Exome Sequencing: Are We Ready?
K. L. Golden-Grant

Strategies to Increase Student Awareness of Genetic Counseling as a Career Option as Perceived by High School Science Teachers
B. N. Guerero

The Impact of Genetic Professionals on Genetic Knowledge in the Cystic Fibrosis (CF) Community: Is One Visit Enough?
E. M. Hogan

Developing a Return of Results Plan in a General Biobank not Focused on a Disease: A Community-Based Approach
K. Johnson

Pre-Test Genetic Counseling for a Non-Hereditary Cancer: Expanding Genetic Counseling Roles
L. Kessler

Patient and Provider Attitudes about the Role of Genetic Counselors in SNP-Based Genetic Risk Assessment for Prostate Cancer
W. Kohlmann

Mountain States Genetics Regional Collaborative Telemedicine Projects Expand Access to Genetic Counseling Services
S. Landgren

Portrait of the Master Genetic Counselor: A Qualitative Investigation of Expertise in Genetic Counseling
B. S. LeRoy

Public Awareness and Perceptions of Genetic Counseling
P. Carrion

The Impact of Independent Billing by Genetic Counselors: Perspectives from Oncologists
A. McRae

Identification and Referral for Cancer Genetic Counseling: Minimal Impact of a Risk Assessment Letter
K. B. Niendorf

The Incorporation of Predictive Genomic Testing into Genetic Counseling Programs
R. Noss

Medical Management Adherence as an Outcome of Genetic Counseling in a Pediatric Setting
S. Polly

Quality Indicators to Evaluate the Collection of Family Health History in Primary Care
K. P. Powell

Novel Application of Electronic Medical Record for Improving Genetics Care
J. D. Riley

Examining the Research Training of Recent Genetic Counseling Graduates
A. Rupchock

Disability Training in Genetic Counseling Training Programs
E. Sanborn

Return of Individual Research Results: A Survey of Genetic Counselors’ Opinions and Experiences
D. Singer

The Electronic Family History Record: Enhancing the Provision of Genomic Medicine
M. N. Strecker

Connecting Genetic Counseling Students with the Disability Community: Our Experience With the Impact Program
J. Su

Evaluating Genetic Counselors Knowledge of Universal Carrier Tests
J. M. Tarpinian

Unveiling Employers’ Envisioned Roles for Clinical Doctorate-Level Genetic Counselors: A Preliminary Analysis
K. Valverde

A Possible Role for Pediatric Genetic Counselors in the International Adoption Process of Children with Special Needs
E. MTP. White

Laboratory Genetic Counseling: Still a “Non-Traditional” Role?
L. Zetzsch
Natera Introduces Next Generation Non-Invasive Prenatal Testing

Natera can detect more chromosomal abnormalities than other non-invasive tests

- NIPT from Natera provides twice the disease detection and is the only test to detect X and Y chromosome abnormalities
- Natera’s Parental Support is the only technology with consistently high detection accuracy across all five chromosomes (>99%): 13, 18, 21, X, and Y.

Natera also offers the following:
- Noninvasive Prenatal Paternity Testing
- Products of Conception (POC) Molecular Karyotype
- Preimplantation Genetic Diagnosis (PGD)
- Natera One™ Multi-Disease Carrier Screening

Contact Mollie Larson at mlarson@natera.com to learn more or to have kits sent directly to your office.

Visit us at the NSGC 31st Annual Education Conference, BOOTH 426

www.natera.com
1-877-476-4743
Natera Introduces Next Generation Non-Invasive Prenatal Testing

- NIPT from Natera provides twice the disease detection and is the only test to detect X and Y chromosome abnormalities.
- Natera's Parental Support is the only technology with consistently high detection accuracy across all five chromosomes (>99%): 13, 18, 21, X, and Y.

Natera also offers the following:
- Noninvasive Prenatal Paternity Testing
- Products of Conception (POC) Molecular Karyotype
- Preimplantation Genetic Diagnosis (PGD)
- Natera One™ Multi-Disease Carrier Screening

Contact Mollie Larson at mlarson@natera.com to learn more or to have kits sent directly to your office.

www.natera.com
1-877-476-4743

Visit us at the NSGC 31st Annual Education Conference, Booth 426

Natera can detect more chromosomal abnormalities than other non-invasive tests.
NSGC Awards and Fellowships

The Jane Engelberg Memorial Fellowship
Response to Genetic Counseling: Understanding the Experience and Needs of Individuals Receiving a Prenatal Diagnosis of Down Syndrome
Katie Sheets, MS, CGC and Blythe Crissman, MS, CGC

The Audrey Heimler Special Projects Award
Heidi Cope, MS, CGC

NSGC Leadership Awards
Natalie Weissberger Paul National Leadership Award
Joan H. Marks, MS
New Leader
Samantha M. Baxter, MS, CGC
Catriona L. Hippman, MSc, CGC
Strategic Leader
Scott M. Weissman, MS, CGC
Outstanding Volunteer
Joy Larsen Haidle, MS, CGC
Leigha Senter-Jamieson, MS, CGC

Best Abstract Awards
Best Full Member Abstract Award
Genetic Counseling for Individuals with Serious Mental Illnesses: The First, and Only, Randomized Controlled Trial
Catriona L. Hippman, MSc, CGC
Beth Fine Kaplan Student Abstract Award
Exploring the Relationship Between Diagnoses of Congenital Anomalies or Genetic Conditions and Postpartum Depression: A Retrospective Study
Meagan Wiesenhart, MS

AEC Planning Subcommittee

NSGC expresses its gratitude to these volunteers for their hard work and dedication.

Chair
Claire Singletary, MS, CGC

Vice-Chair
Quinn Stein, MS, CGC

Subcommittee Members
Mary Jarvis Ahrens, MS, CGC
Julie Culver, MS, CGC
Patricia Devers, MS, CGC
Katherine Dunn, MS, LCGC
Lori AH Erby, Phd, CGC
Lauren Hache, MS, CGC
Catherine Vendola, MS, CGC
Meredith Weaver, PhD, ScM, CGC
Emily Windsor, MS, CGC

Abstract Chair
Brandie Leach, MS, CGC

Abstract Vice-Chair
Anne C. Madeo, MS, CGC

Abstract Workgroup
Sharon Aufox, MS, CGC
Cecelia Bellcross, PhD, MS, CGC
Meg Bradbury, MS, CGC
Kari Haag Branham, MS, CGC
Pamela Callum, MS, CGC
Molly Daniels, MS, CGC
Tiffani DeMarco, MS
Melissa Dempsey, MS, CGC
Sandra Donkervoort, MS, CGC
Heather Douglas, MS, CGC
Emily Edelman, MS, CGC
Jamie Fong, MS, CGC
Shanna Gustafson, MS, MPH, CGC
Catriona Hippman, MSc, CGC
Cindy James, ScM, PhD, CGC
Emily James, MS, CGC
Yelena Kemel, MS, ScM, CGC
Katie Krepkovich, MS, CGC
Shawn Lipinski, ScM, CGC
Sarah Noblin, MS, CGC
Toni Pollin, PhD, MS, CGC
Christina Rigelsky, MS, CGC
Carly Siskind, MS, CGC
Christine Spaeth, MS, CGC
Shelia Solomon, MS, CGC
Peggy Walker, MS, CGC
Beverly Yashar, PhD, MS, CGC
Heather Zierhut, MS, CGC

Outreach Coordinator
Katherine Lafferty, MS, CGC

Education Committee Chair
Leigha Senter-Jamieson, MS, CGC

Education Committee Vice-Chair
Kelly Jackson, MS, CGC

Education Committee Board Liaison
Janet Williams, MS, CGC
Better treatment starts with the right diagnosis.

To learn more about genetic testing, visit Athena Diagnostics at booth 409 or online at AthenaDiagnostics.com

©2012 Athena Diagnostics. Athena Diagnostics and the Athena Diagnostics logo are registered trademarks of Athena Diagnostics, Inc.
Networking Activities and Business Meetings

**Welcome Reception**
**Wednesday, October 24 • 6:30 pm – 8:00 pm • Hall D**
Make new contacts and greet your friends as you preview the vendors and their services in the Exhibitor Suite. Join your colleagues for this special kickoff to the AEC. Light hors d’oeuvres and cash bar will be available.

**State of the Society Address**
**Thursday, October 25 • 10:15 am – 10:45 am • Room 302/304/306**
Join President Brenda Finucane, MS, CGC, as she provides an overview of NSGC activities and accomplishments over the past year. Brenda will review NSGC’s advocacy efforts, strategic initiatives and provide highlights from 2012.

**NSGC Annual Business Meeting**
**Friday, October 26 • 4:00 pm – 4:45 pm • Room 302/304/306**

**Incoming Presidential Address**
**Saturday, October 27 • 9:00 am – 9:30 am • Room 302/304/306**
Hear NSGC President Elect Rebecca Nagy, MS, CGC, as she introduces herself to NSGC members and outlines her vision for NSGC in 2013.

**ABGC Annual Business Meeting**
**Saturday, October 27 • 12:30 pm – 2:00 pm • Room 302/304/306**

**Breaks and Lunches**
There are many opportunities to meet and mingle with your colleagues throughout the conference. Make note of these scheduled breaks to network with your peers:

- **Thursday, October 25**
  - 10:00 am – 10:15 am Level 3 Foyer
  - 4:15 pm – 4:30 pm Level 2 Foyer

- **Friday, October 26**
  - 9:45 am – 10:00 am Level 3 Foyer
  - 3:30 pm – 4:00 pm Hall D

- **Saturday, October 27**
  - 10:30 am – 10:45 am Level 2 Foyer

EXPANDING
the Spectrum of Genomic Health

NSGC 2012
BOULDER ABORTION CLINIC

Specializing in Late Abortion for Fetal Disorders
Quality Care for Women Since 1973

Warren M. Hern, MD, MPH, PhD

Director
American Board of Preventive Medicine
Fellow, American College of Preventive Medicine
Assistant Clinical Professor, Department of Obstetrics & Gynecology
University of Colorado Health Sciences Center

Author
Abortion Practice
Philadelphia: J.B. Lippincott, 1984
Boulder: Alpenglo Graphics, 1990
(soft cover edition)

- Outpatient abortion over 30 menstrual weeks for selected patients with
documented fetal anomaly, fetal demise, or medical indications
- Routine preoperative ultrasound evaluation for all patients
- Routine preoperative use of laminaria for maximum safety
- Individual counseling and support
- Highly experienced and dedicated professional staff
- Tradition of research and teaching in abortion services
- Founding institutional member, National Abortion Federation
- Bilingual staff and physician: fluent in Spanish, Portuguese, and Italian
- Recent research publications on request
- Consultations on request

1130 Alpine Avenue, Boulder, CO 80304
Tel: (303) 447-1361 • (800) 535-1287 • Fax: (303) 447-0020
www.drhern.com
<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott</td>
<td>327</td>
</tr>
<tr>
<td>Actelion Pharmaceuticals US, Inc</td>
<td>101</td>
</tr>
<tr>
<td>Advanced Abortion Care Referral Service</td>
<td>129</td>
</tr>
<tr>
<td>Ambry Genetics*</td>
<td>109</td>
</tr>
<tr>
<td>American Board of Genetic Counseling (ABGC)</td>
<td>421</td>
</tr>
<tr>
<td>Ariosa Diagnostics</td>
<td>415</td>
</tr>
<tr>
<td>ARUP Laboratories</td>
<td>114</td>
</tr>
<tr>
<td>Asuragen, Inc.</td>
<td>223</td>
</tr>
<tr>
<td>Athena Diagnostics, Inc.</td>
<td>409</td>
</tr>
<tr>
<td>Baby’s First Test</td>
<td>402</td>
</tr>
<tr>
<td>Baylor College of Medicine, Medical Genetics Laboratories*</td>
<td>201</td>
</tr>
<tr>
<td>BioMarin Pharmaceutical Inc.</td>
<td>228</td>
</tr>
<tr>
<td>Boulder Abortion Clinic, P.C.*</td>
<td>216</td>
</tr>
<tr>
<td>Bright Pink, NFP</td>
<td>307</td>
</tr>
<tr>
<td>Cancer Resource Foundation, Inc.</td>
<td>119</td>
</tr>
<tr>
<td>Casey Eye Institute Molecular Diagnostic Laboratory</td>
<td>406</td>
</tr>
<tr>
<td>CBR® (Cord Blood Registry®)</td>
<td>310</td>
</tr>
<tr>
<td>Center for Fetal Diagnosis &amp; Treatment at CHOP</td>
<td>110</td>
</tr>
<tr>
<td>City of Hope — Clinical Molecular Diagnostic Laboratory</td>
<td>309</td>
</tr>
<tr>
<td>CombiMatrix Diagnostics</td>
<td>306</td>
</tr>
<tr>
<td>Connective Tissue Gene Tests</td>
<td>221</td>
</tr>
<tr>
<td>Counsyl</td>
<td>404</td>
</tr>
<tr>
<td>Denver Genetic Laboratories, University of Colorado</td>
<td>104</td>
</tr>
<tr>
<td>Early Brain Development in Children with Fragile X</td>
<td>122</td>
</tr>
<tr>
<td>Edimer Pharmaceuticals</td>
<td>226</td>
</tr>
<tr>
<td>Emory Genetics Laboratory</td>
<td>106</td>
</tr>
<tr>
<td>Fetal Repair of Myelomeningocele At Vanderbilt</td>
<td>321</td>
</tr>
<tr>
<td>FORCE: Facing Our Risk of Cancer Empowered</td>
<td>128</td>
</tr>
<tr>
<td>Geisinger Health System</td>
<td>126</td>
</tr>
<tr>
<td>GeneDx*</td>
<td>215</td>
</tr>
<tr>
<td>Genesis Genetics Institute</td>
<td>400</td>
</tr>
<tr>
<td>GenPath Women’s Health</td>
<td>214</td>
</tr>
<tr>
<td>Genzyme, a Sanofi Company</td>
<td>227</td>
</tr>
<tr>
<td>Good Start Genetics</td>
<td>322</td>
</tr>
<tr>
<td>Illumina, Inc.*</td>
<td>311</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>IntegraGen, Inc.</td>
<td>320</td>
</tr>
<tr>
<td>Integrated Genetics*</td>
<td>301</td>
</tr>
<tr>
<td>Jane Engelberg Memorial Fellowship (JEMF)</td>
<td>407</td>
</tr>
<tr>
<td>Kaiser Genetics - Northern California</td>
<td>323</td>
</tr>
<tr>
<td>Laboratory for Molecular Medicine, PCPGM</td>
<td>408</td>
</tr>
<tr>
<td>Mayo Medical Laboratories</td>
<td>127</td>
</tr>
<tr>
<td>Myriad Genetic Laboratories, Inc.*</td>
<td>315</td>
</tr>
<tr>
<td>Natera*</td>
<td>426</td>
</tr>
<tr>
<td>National Abortion Federation - Hotline Fund</td>
<td>116</td>
</tr>
<tr>
<td>National Society of Genetic Counselors</td>
<td>423</td>
</tr>
<tr>
<td>NextGx Dx</td>
<td>417</td>
</tr>
<tr>
<td>NSGC Cancer SIG</td>
<td>419</td>
</tr>
<tr>
<td>NTD Labs &amp; Signature Genomics from PerkinElmer</td>
<td>410</td>
</tr>
<tr>
<td>Organization of Teratology Information Specialists</td>
<td>222</td>
</tr>
<tr>
<td>Orphan Europe Recordati Group</td>
<td>418</td>
</tr>
<tr>
<td>Pfizer*</td>
<td>329</td>
</tr>
<tr>
<td>Prevention Genetics LLC</td>
<td>414</td>
</tr>
<tr>
<td>Progeny Software, LLC</td>
<td>103</td>
</tr>
<tr>
<td>Quest Diagnostics*</td>
<td>207</td>
</tr>
<tr>
<td>Recombine</td>
<td>121</td>
</tr>
<tr>
<td>Reproductive Genetics Institute</td>
<td>117</td>
</tr>
<tr>
<td>Reprogenetics</td>
<td>220</td>
</tr>
<tr>
<td>Sequenom Center for Molecular Medicine*</td>
<td>100</td>
</tr>
<tr>
<td>Sharsheret</td>
<td>305</td>
</tr>
<tr>
<td>Southwestern Women’s Options</td>
<td>420</td>
</tr>
<tr>
<td>St. Louis Fetal Care Institute</td>
<td>118</td>
</tr>
<tr>
<td>The Greenwood Genetic Center</td>
<td>123</td>
</tr>
<tr>
<td>The Heart Institute Diagnostic Laboratory</td>
<td>120</td>
</tr>
<tr>
<td>The University of Chicago Genetic Services</td>
<td>405</td>
</tr>
<tr>
<td>Trakgene</td>
<td>115</td>
</tr>
<tr>
<td>Transgenomic Labs</td>
<td>416</td>
</tr>
<tr>
<td>UAB Medical Genomics Laboratory</td>
<td>422</td>
</tr>
<tr>
<td>UCLA Clinical Genomics Center</td>
<td>211</td>
</tr>
<tr>
<td>University of Washington Reference Lab Services</td>
<td>429</td>
</tr>
<tr>
<td>Verinata Health Inc.*</td>
<td>200</td>
</tr>
<tr>
<td>Victor Center for the Prevention of Jewish Genetic Diseases</td>
<td>319</td>
</tr>
</tbody>
</table>

* Denotes an NSGC Sponsor
Comprehensive
PreventionGenetics provides clinical Sanger sequencing, Deletion/Duplication testing via aCGH, Next-Gen Sequencing and DNA Banking services for the medical and research communities both nationally and internationally.

Convenience
Pre-paid Clinical Testing kits and DNA Banking kits now available for our clients.

Service
We are rapidly expanding and have recently hired a Director of Genetic Counseling & Client Services to continue our long-standing history of offering excellent customer service.

Quality
Our extensive knowledge and experience with Sanger sequencing, Del/Dup via aCGH and Next-Gen technology ensures that you get high quality results.

Low Cost
Our competitive prices are among the lowest in the industry.

Visit us at Booth #414 for your chance to win an Amazon Kindle.

Meet our new Director of Genetic Counseling

3700 Downwind Drive, Marshfield, Wisconsin 54449
Phone 715.387.0484
FAX 715.384.3661

PREVENTION GENETICS
DISEASE PREVENTION THROUGH GENETIC TESTING

PUT US TO THE TEST
www.preventiongenetics.com
Abbott
Booth#: 327
Phone: 847.937.6100
www.abbott.com
Abbott is a global, broad-based healthcare company devoted to discovering new medicines, new technologies and new ways to manage health. Our products span the continuum of care, from nutritional products to medical devices and pharmaceutical therapies. Our comprehensive product line encircles life itself — addressing important health needs for all ages.

Actelion Pharmaceuticals US, Inc
Booth#: 101
Phone: 650.624.6900
www.actelion.com
Actelion Pharmaceuticals Ltd. is a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland, that focuses on the discovery, development and commercialization of innovative treatments to serve high unmet medical needs.

Advanced Abortion Care Referral Service
Booth#: 129
Phone: 856.667.5910
Email: jmoore@cherryhillwomenscenter.com
www.cherryhillwomenscenter.com
Providing safe and compassionate referrals for later abortion care for women and their families.

Ambry Genetics*
Booth#: 109
Phone: 949.900.5500
www.ambrygen.com
Ambry Genetics, an innovator in genetic testing and leader in next generation sequencing technology, offers a comprehensive menu of diagnostic tests for more than 300 genes, plus whole exome sequencing. Ambry’s insurance pre-verification, easy ordering and enhanced reporting let you focus on the patient instead of the paperwork.

American Board of Genetic Counseling, Inc. (ABGC)
Booth#: 421
Phone: 913.895.4617
Email: info@abgc.net
www.abgc.net
The American Board of Genetic Counseling establishes standards of competence through accreditation of graduate training programs and certification and recertification of genetic counselors to advance the profession and protect the public.

Ariosa Diagnostics
Booth#: 415
Phone: 855.9.ARIOSA (855.927.4672)
Email: clientservices@ariosadx.com
www.ariosadx.com
Ariosa Diagnostics, Inc. is committed to providing safe, highly accurate and affordable tests for maternal and fetal health. Ariosa’s Harmony Prenatal Test offers reliable detection of the common trisomies associated with Down syndrome and other conditions.

ARUP Laboratories
Booth#: 114
Phone: 800.522.2787
Email: clientservices@aruplab.com
www.arup.com/genetics
A nonprofit enterprise of the University of Utah, ARUP Laboratories is a leading national reference laboratory offering esoteric molecular assays and a comprehensive genetics test menu, including biochemical, cytogenetic and molecular genetic testing.

Asuragen, Inc.
Booth#: 223
Phone: 512.681.5200
Email: clinicallabsupport@asuragen.com
www.asuragen.com
Asuragen Clinical Laboratory offers a suite of Fragile X testing methodologies including Xpansion Interpreter™, a breakthrough molecular diagnostic test that utilizes novel PCR technologies to detect stabilizing AGG sequences within the FMR1 gene in order to refine the risk of expansion in future generations.

Athena Diagnostics, Inc.
Booth#: 409
Phone: 800.394.4493
Email: info@athenadiagnostics.com
www.athenadiagnostics.com
Athena Diagnostics, a leader in specialized diagnostic testing, provides the most comprehensive test menu for neurological, endocrine and renal conditions through more than 350 diagnostic tests.

Baby’s First Test
Booth#: 402
Phone: 202.966.5557
Email: info@babysfirsttest.org
www.babysfirsttest.org
Baby’s First Test is the nation’s newborn screening education center for families and providers. This site provides information on all of the conditions screened for, details screening procedures and has information on state panels.

Baylor College of Medicine, Medical Genetics Laboratories*
Booth#: 201
Phone: 713.798.6556
Email: genetictest@bcm.edu
www bcmgeneticlabs.org
Baylor College of Medicine, Medical Genetics Laboratories offer a broad range of diagnostic genetics tests including DNA diagnostics, sequencing, cytogenetics, FISH diagnostics, cancer cytogenetics, chromosomal microarray analysis, whole exome sequencing, biochemical genetics, and Mitochondrial DNA analysis. Please visit our booth for more information!

BioMarin Pharmaceutical Inc.
Booth#: 228
Phone: 415.506.6700
Email: kward@bmrn.com
www.bmrn.com
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. Approved products include the first and only enzyme replacement therapies for MPS I and MPS VI and the first and only FDA-approved medication for PKU. Visit www.BMRN.com to learn more.

Boulder Abortion Clinic, P.C.*
Booth#: 216
Phone: 303.447.1361 / 800.535.1287
Email: bachern@msn.com
www.drhern.com
Our purpose is to provide the safest possible abortion care and termination of pregnancies for fetal anomalies or medical indications. We provide this care in a confidential, comfortable, humane, and dignified outpatient setting.

Bright Pink, NFP
Booth#: 307
Phone: 312.787.4412
Email: brightpink@bebrightpink.org
http://www.bebrightpink.org
Bright Pink is a national non-profit organization that provides education and support to young women who are at high risk for breast and ovarian cancer. We arm young women with knowledge, options and a great attitude, and offer companionship and empathy during their journey. We empower them to take control of their breast and ovarian health and, in turn, grant them the freedom and peace of mind to live beautiful and fulfilling lives.

Cancer Resource Foundation, Inc.
Booth#: 119
Phone: 508.630.2242
Email: info@cancer1source.org
www.cancer1source.org
The Cancer Resource Foundation’s (CRF) mission is to advocate and provide support for the prevention, early detection, diagnosis, treatment and survivorship of cancer through patient assistance, education and research.

Casey Eye Institute Molecular Diagnostic Laboratory
Booth#: 406
Phone: 503.494.5838
Email: chiang@ohsu.edu
www.ohsucasey.com/diagnostics
The Casey Eye Institute Molecular Diagnostic Laboratory is a CLIA certified laboratory providing comprehensive molecular testing for genetic diseases involving the eye. Our mission as a laboratory is to identify the causative genetic mutation(s) for every person in a timely and cost-effective manner.

CBR ® (Cord Blood Registry®)
Booth#: 310
Phone: 800.588.0258
Email: providers@cordblood.com
www.cordblood.com
CBR® (Cord Blood Registry®) is the largest, most experienced newborn stem cell bank in the world. CBR has banked stem cells for more than 400,000 children, and has released more cord blood for treatment than any other family bank.

Center for Fetal Diagnosis & Treatment at CHOP
Booth#: 110
Phone: 800.IN-UTERO (468.8376)
Email: fetalsurgery@email.chop.edu
www.fetalsurgery.chop.edu
For pregnancies complicated by birth defects, the Center is one of the most experienced programs in the world, providing the complete spectrum of care — expert prenatal diagnosis, fetal therapy including fetal repair of spina bifida, delivery and postnatal treatment.
The City of Hope Molecular Diagnostic Laboratory (CMDL) specializes in clinical genetic testing services for cancer predisposition, coagulopathies, connective tissue disorders, muscular dystrophies, neuropsychiatric disorders and pharmacogenetics. For more up-to-date information, please visit http://cmdl.cityofhope.org.

CombiMatrix Diagnostics

Phone: 800.710.0624
Email: info@cmdiagnostics.com
www.combimatrix.com

CombiMatrix Diagnostics, an industry-leader in genomic testing, offers clinicians a broad menu of innovative microarray tests. We provide state-of-the-art genetic testing services in the areas of Prenatal & Reproductive Health (including microarray, FISH & chromosome analysis); Pediatrics/Postnatal; and Hematology-Oncology.

Connective Tissue Gene Tests

Phone: 484.244.2900
Email: leena.alakokko@ctgt.net
www.ctgt.net

CTGT is committed to providing the broadest range of molecular diagnostics for inherited connective tissue disorders – over 180 tests and growing rapidly. CTGT has high test sensitivity, fast service, expert advice and superior customer service.

Counsyl

Phone: 888.COUNSyl (888.268.6795)
Email: info@counsyl.com
www.counsyl.com

Counsyl has developed an affordable and universal pre-pregnancy test which every parent can take to increase her chances of having a healthy child. The test is covered by insurance and prescribed by thousands of physicians internationally.

Denver Genetic Laboratories, University of Colorado

Phone: 303.724.3826 (Biochemical); 303.724.3801 (DNA)
Email: michael.woontner@ucdenver.edu (Biochemical); elaine.spector@ucdenver.edu (DNA)
www.denvergenetics.org

Denver Genetic Laboratories include the DNA Diagnostic Laboratory (Dr. Elaine Spector) and Biochemical Genetics Lab (Dr. Stephen Goodman), University of Colorado. Our molecular, biochemical, mitochondrial, clinical and cytogenetics expertise is backed by ongoing academic research.

Early Brain Development in Children with Fragile X

Phone: 800.793.5715 or 888.845.6786
Email: ibisnetwork@gmail.com
www.ibisnetwork.org/fragilex

A longitudinal MRI study focusing on brain development in infants with Fragile X. Looking for participants 0-24 months with a Fragile X diagnosis. Scans and assessments are conducted at 6, 12 and 24 months of age.

Edimer Pharmaceuticals

Phone: 617.758.4300
Email: Tessa@edimerpharma.com
www.edimerpharma.com

Edimer Pharmaceuticals is developing EDI200, a treatment for X-linked Hydropsidrotic Ectodermal Dysplasia. Edimer has an active IND for EDI200; clinical studies will begin Q4 2012. EDI200 has Orphan Drug designation in the US and Europe.

Emory Genetics Laboratory

Phone: 404.778.8499
Email: kelliannemartini@emory.edu
www.geneticslab.emory.edu

Emory Genetics Laboratory (EGL) is a worldwide leader in rare disease clinical genetic testing. EGL’s biochemical, cytogenetic, and molecular laboratories perform integrated and comprehensive testing including whole exome sequencing, prenatal microarrays and metabolic disorder testing.

Fetal Repair of Myelomeningocele At Vanderbilt

Phone: 877.875.3737
Email: mary.dabrowiak@vanderbilt.edu
http://www.childrenshospital.vanderbilt.org/fetalcenter

Vanderbilt University Medical Center is the only centrally located facility in the U.S. currently offering prenatal treatment for myelomenigocele. We are unique in our focus on the care of both mom and unborn baby.

FORCE: Facing Our Risk of Cancer Empowered

Phone: 866.288.RISK (7475)
Email: info@facingsourrisk.org
www.facingsourrisk.org

FORCE is a national nonprofit dedicated to fighting hereditary breast and ovarian cancer. With 50 outreach groups throughout the US, FORCE programs include education, support, advocacy and research specific to BRCA mutations and hereditary cancers.

Geisenger Health System

Phone: 570.214.9275/800.845.7112
Email: jheid1@geisenger.edu
www.geisinger.org

Geisinger serves 3 million people in Northeastern and Central Pennsylvania, and has been nationally recognized for research, innovation and quality care. An electronic health record connects multiple hospitals, community practice sites and 900 physicians.

GeneDx

Phone: 301.519.2100
www.genedx.com

GeneDx tests for more than 350 rare Mendelian disorders using DNA sequencing and deletion/duplication analysis of the associated gene(s), and offers oligonucleotide microarray-based testing and next-generation sequencing based panels for cardiac, mitochondrial and neurodevelopmental disorders.

Genesys Genetics Institute

Phone: 313.259.5507
Email:info@counsyl.com
www.genesysgenetics.org

Genesys Genetics Institute is the pioneer of pre-implantation testing of embryos for inherited genetic abnormalities. Founded by world renowned scientist Dr. Mark Hughes MD, PhD., one of the original scientists working on the National Institutes of Health’s Human Genome Project, Dr. Hughes’ team was largely responsible for discovering pre-implantation genetic diagnosis (PGD) as a clinical practice and performed the first successful cases in the world.

Good Start Genetics, Inc.

Phone: 617.714.0800
www.gsgenetics.com

Good Start Genetics® is a molecular diagnostics company improving the standard of care for routine genetic carrier screening. By harnessing best-in-class technologies, GoodStart Select ™ delivers relevant results through simple testing and reporting solutions tailored to each clinician and patient and supported by customer care.

Illumina, Inc.*

Phone: 858.202.4566
Email: info@illumina.com
www.illumina.com

Illumina’s technologies are providing the foundation for understanding disease at the molecular level. Our genotyping and sequencing technologies are fueling the emerging field of consumer genomics and are beginning to be applied to create innovations in molecular diagnostics.
IntegraGen, Inc.

Booth#: 320
Phone: 877.992.7475
Email: larry.yost@integragen.com
www.arisktest.com

IntegraGen is a biotechnology company dedicated to molecular biomarker discovery. The Company has recently launched the ARISK™ Test, a genetic screening tool for the early identification of children at risk for autism spectrum disorder.

Integrated Genetics*

Booth#: 301
Phone: 800.848.4436
www.integratedgenetics.com

Integrated Genetics is a leading provider of reproductive genetic testing services with an expansive menu of complex tests in prenatal and postnatal genetic testing. For more information, visit www.integratedgenetics.com.

Jane Engelberg Memorial Fellowship (JEMF)

Booth#: 407
Email: kevin.sweet@osumc.edu
www.osumc.edu

The prestigious Jane Engelberg Memorial Fellowship is awarded by the NSGC in memory of Jane Engelberg, MS to promote the professional development of individual counselors and to improve our practice by providing support for scholarly investigation.

Kaiser Genetics - Northern California

Booth#: 323
Email: Cindy.E.Soliday@kp.org
www.genetics.kp.org

PRACTICE WHAT YOU BELIEVE, PRACTICE AT KAISER PERMANENTE! Kaiser Genetics is the employer of choice for over 70 genetic counselors in Northern California. Stop by our booth to learn more about our rewarding positions!

Laboratory for Molecular Medicine, PCPGM

Booth#: 408
Phone: 617.768.8500
Email: lmm@partners.org
http://pcpgm.partners.org/lmm

The Harvard-affiliated Laboratory for Molecular Medicine is a CLIA-certified molecular diagnostic laboratory within the Partners Healthcare Center for Personalized Genetic Medicine. Our major areas of focus are cardiovascular diseases and syndromes, cancer and hearing loss.

Mayo Medical Laboratories

Booth#: 127
Phone: 800.533.1710
Email: mml@mayo.edu
www.mayomedicallaboratories.com

Mayo Medical Laboratories is a global reference laboratory operating within Mayo Clinic’s Department of Laboratory Medicine and Pathology. Mayo Medical Laboratories’ personal approach to patient care extends into every aspect of our business.

Myriad Genetic Laboratories, Inc.*

Booth#: 315
Phone: 800.469.7423
Email: cscommentis@myriad.com
www.myriadpro.com

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient’s lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.

Natera*

Booth#: 426
Phone: 650.249.9090x357
Email: ksong@natera.com
www.natera.com

Natera provides reproductive genetic tests using bioinformatics in combination with SNP microarrays. Tests include preimplantation genetic diagnosis (PGD) for IVF, rapid turnaround molecular karyotyping of products of conception, non-invasive prenatal paternity testing, and non-invasive prenatal diagnosis.

National Abortion Federation – Hotline Fund

Booth#: 116
Phone: 800.772.9100
Email: chhebert@prochoice.org
www.prochoice.org

The NAF Hotline is the only toll-free source of information about abortion and referrals to providers of quality care in the U.S. and Canada. We provide callers unbiased, factual information in English, Spanish and French.

National Society of Genetic Counselors (NSGC)

Booth#: 423
Phone: 312.321.6834
Email: nsgc@nsgc.org
www.nsgc.org

The National Society of Genetic Counselors (NSGC) advances the roles of genetic counselors in healthcare by fostering education, research, and public policy to ensure the availability of quality genetic services. Visit the booth for membership services information, to view products and more.

NextGxDx

Booth#: 417
Phone: 615.236.4569
Email: info@nextgxdx.com
www.nextgxdx.com

Web-based marketplace that offers one-stop shopping for genetic testing. NextGxDx provides genetic counselors with tools to search, compare, order and receive test results online.

NSGC Cancer SIG

Booth#: 419

Members of the NSGC Cancer SIG will be available during breaks to answer your questions about SIG projects and how you can get involved. Please stop by to view and receive samples of materials that have been developed by the SIG recently.

NTD Labs & Signature Genomics from PerkinElmer

Booth#: 410
Phone: 888.NTD.LABS or 877.SigChip
Email: ntdlabs@perkinelmer.com;
info@www.ntdlabs.com
www.signaturegenomics.com

NTD Labs offers the most accurate first trimester aneuploidy screening. Signature Genomics offers a range of prenatal diagnostic testing to suit every patient case. PerkinElmer Labs give providers critical information needed to ensure timely management of the pregnancy.

Organization of Teratology Information Specialists

Booth#: 222
Phone: 877.311.8972
www.otispregnancy.org

Healthcare providers and their patients can utilize OTIS as a resource for accurate and current information about the possible effects of medications and other environmental exposures during pregnancy and lactation.

Orphan Europe Recordati Group

Booth#: 418
Phone: 949.637.5199
Email: us-west@orphan-europe.com
www.orphan-europe.com

At Orphan Europe, part of the Recordati Group, we are fully committed to improving the lives of people suffering from rare diseases through effective and safe treatments. Our products treat rare diseases and rare diseases only. In cooperation with the scientific community and patient organizations, we want to assure that everything is done from our side to make life as easy as possible for these patients.

Pfizer*

Booth#: 329
Phone: 212.733.2323
www.pfizer.com

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Prevention Genetics LLC

Booth#: 414
Phone: 715.387.0484
Email: s.samuels@preventiongenetics.com
www.preventiongenetics.com

Prevention Genetics offers over 500 clinical DNA sequencing tests and DNA banking services. We provide fast turnaround times, outstanding personalized service and the most reasonable prices in the industry. We are CLIA accredited. Please visit www.preventiongenetics.com.

Progeny Software, LLC

Booth#: 103
Phone: 800.progeny (776.4369)
Email: info@progenygenetics.com
www.progenygenetics.com

Progeny Software provides customizable software to manage pedigrees, genotypes and samples for genetic counselors, clinicians and scientists worldwide. Our NEW web-based Family History Questionnaire captures patient data online or via tablet, automatically drawing the pedigree.

Quest Diagnostics*

Booth#: 207
Phone: 866.MYQUEST
www.questdiagnostics.com

Quest Diagnostics, the world’s leading provider of diagnostic testing, information and services, offers a comprehensive test menu including prenatal and genetics, toxicology and immunology, endocrinology and oncology.
Southwestern Women’s Options
Booth#: 420
Phone: 505.242.7512
Email: boyd02@covad.net
www.curtisboydmd.com
Curtis Boyd, MD-owned clinics provide a full range of medical and surgical abortion services. The Albuquerque office specializes in third trimester abortion care and offers a unique Fetal Indications Program geared to the special needs of the patient and her family.

St. Louis Fetal Care Institute
Booth#: 118
Phone: 314.268.4037
Email: fetalcare@ssmhcm.com
www.stlouisfetalcare.com
The St. Louis Fetal Care Institute is a comprehensive diagnostic and therapeutic program that specializes in treating congenital problems and structural abnormalities in babies both in the womb and after birth.

RGI is a world-renowned provider of preimplantation genetic diagnosis (PGD) laboratory offering 24 chromosome aCGH for aneuploidy, translocations and inversions, PGD for single gene disorders and HLA matching, aCGH for POC testing, and FISH on sperm.

Recombine
Booth#: 121
Phone: 855.OUR.GENES
Email: info@recombine.com
www.recombine.com
Recombine is a clinical genetic testing company. We provide a complete and integrated service covering everything from sample collection to genetic counseling. We simplify the genetic testing process so you can focus on caring for your patients.

Reproductive Genetics Institute
Booth#: 117
Phone: 773.472.4900
Email: rgiworld@gmail.com
www.reproductivegenetics.com
RGI is a world-renowned provider of preimplantation testing (PGT) with expertise spanning three decades. PGT testing is available through RGI for nearly any single-gene condition, chromosome rearrangements or aneuploidy testing via PCR, FISH or aCGH.

Reprogenetics
Booth#: 220
Phone: 973.436.5003
Email: jfischer@reprogenetics.com
www.reprogenetics.com
Reprogenetics is a full-service preimplantation genetic diagnosis (PGD) laboratory offering 24 chromosome aCGH for aneuploidy, translocations and inversions, PGD for single gene disorders and HLA matching, aCGH for POC testing, and FISH on sperm.

Sequenom Center for Molecular Medicine*
Booth#: 100
Phone: 877.821.7266
Email: info@sequenomcm.com
www.sequenomCMM.com
Sequenom CMM® is a wholly owned subsidiary of Sequenom, Inc., and a CLIA-certified, CAP accredited molecular diagnostics laboratory dedicated to the development and commercialization of laboratory-developed tests for prenatal and ophthalmic conditions. Utilizing innovative proprietary technologies, Sequenom CMM provides test results that can be used by ordering clinicians in managing patient care. New for 2012 is the MaterniT21™ PLUS laboratory-developed test, a noninvasive test that analyzes the relative amount of chromosomes 21, 18 and 13 from a maternal blood sample. Other laboratory-developed tests include SensiGene® Cystic Fibrosis Carrier Screening, SensiGene® Fetal RHD Genotyping and RetnaGene™ AMD.

Sharsheret
Booth#: 305
Phone: 866.474.2774
Email: jthompson@sharsheret.org
www.sharsheret.org
Sharsheret is a national not-for-profit organization supporting young women and their families, of all Jewish backgrounds, facing breast cancer. Our mission is to offer a community of support to women diagnosed with breast cancer or at increased genetic risk, by fostering culturally-relevant individualization connections with networks of peers, health professionals and related resources.

Southwestern Women’s Options
Booth#: 420
Phone: 505.242.7512
Email: boyd02@covad.net
www.curtisboydmd.com
Curtis Boyd, MD-owned clinics provide a full range of medical and surgical abortion services. The Albuquerque office specializes in third trimester abortion care and offers a unique Fetal Indications Program geared to the special needs of the patient and her family.

St. Louis Fetal Care Institute
Booth#: 118
Phone: 314.268.4037
Email: fetalcare@ssmhcm.com
www.stlouisfetalcare.com
The St. Louis Fetal Care Institute is a comprehensive diagnostic and therapeutic program that specializes in treating congenital problems and structural abnormalities in babies both in the womb and after birth.

Recombine
Booth#: 121
Phone: 855.OUR.GENES
Email: info@recombine.com
www.recombine.com
Recombine is a clinical genetic testing company. We provide a complete and integrated service covering everything from sample collection to genetic counseling. We simplify the genetic testing process so you can focus on caring for your patients.

Reproductive Genetics Institute
Booth#: 117
Phone: 773.472.4900
Email: rgiworld@gmail.com
www.reproductivegenetics.com
RGI is a world-renowned provider of preimplantation testing (PGT) with expertise spanning three decades. PGT testing is available through RGI for nearly any single-gene condition, chromosome rearrangements or aneuploidy testing via PCR, FISH or aCGH.

Reprogenetics
Booth#: 220
Phone: 973.436.5003
Email: jfischer@reprogenetics.com
www.reprogenetics.com
Reprogenetics is a full-service preimplantation genetic diagnosis (PGD) laboratory offering 24 chromosome aCGH for aneuploidy, translocations and inversions, PGD for single gene disorders and HLA matching, aCGH for POC testing, and FISH on sperm.

Sequenom Center for Molecular Medicine*
Booth#: 100
Phone: 877.821.7266
Email: info@sequenomcm.com
www.sequenomCMM.com
Sequenom CMM® is a wholly owned subsidiary of Sequenom, Inc., and a CLIA-certified, CAP accredited molecular diagnostics laboratory dedicated to the development and commercialization of laboratory-developed tests for prenatal and ophthalmic conditions. Utilizing innovative proprietary technologies, Sequenom CMM provides test results that can be used by ordering clinicians in managing patient care. New for 2012 is the MaterniT21™ PLUS laboratory-developed test, a noninvasive test that analyzes the relative amount of chromosomes 21, 18 and 13 from a maternal blood sample. Other laboratory-developed tests include SensiGene® Cystic Fibrosis Carrier Screening, SensiGene® Fetal RHD Genotyping and RetnaGene™ AMD.

Sharsheret
Booth#: 305
Phone: 866.474.2774
Email: jthompson@sharsheret.org
www.sharsheret.org
Sharsheret is a national not-for-profit organization supporting young women and their families, of all Jewish backgrounds, facing breast cancer. Our mission is to offer a community of support to women diagnosed with breast cancer or at increased genetic risk, by fostering culturally-relevant individualization connections with networks of peers, health professionals and related resources.

Southwestern Women’s Options
Booth#: 420
Phone: 505.242.7512
Email: boyd02@covad.net
www.curtisboydmd.com
Curtis Boyd, MD-owned clinics provide a full range of medical and surgical abortion services. The Albuquerque office specializes in third trimester abortion care and offers a unique Fetal Indications Program geared to the special needs of the patient and her family.

St. Louis Fetal Care Institute
Booth#: 118
Phone: 314.268.4037
Email: fetalcare@ssmhcm.com
www.stlouisfetalcare.com
The St. Louis Fetal Care Institute is a comprehensive diagnostic and therapeutic program that specializes in treating congenital problems and structural abnormalities in babies both in the womb and after birth.

Recombine
Booth#: 121
Phone: 855.OUR.GENES
Email: info@recombine.com
www.recombine.com
Recombine is a clinical genetic testing company. We provide a complete and integrated service covering everything from sample collection to genetic counseling. We simplify the genetic testing process so you can focus on caring for your patients.

Reproductive Genetics Institute
Booth#: 117
Phone: 773.472.4900
Email: rgiworld@gmail.com
www.reproductivegenetics.com
RGI is a world-renowned provider of preimplantation testing (PGT) with expertise spanning three decades. PGT testing is available through RGI for nearly any single-gene condition, chromosome rearrangements or aneuploidy testing via PCR, FISH or aCGH.

Reprogenetics
Booth#: 220
Phone: 973.436.5003
Email: jfischer@reprogenetics.com
www.reprogenetics.com
Reprogenetics is a full-service preimplantation genetic diagnosis (PGD) laboratory offering 24 chromosome aCGH for aneuploidy, translocations and inversions, PGD for single gene disorders and HLA matching, aCGH for POC testing, and FISH on sperm.

Sequenom Center for Molecular Medicine*
Booth#: 100
Phone: 877.821.7266
Email: info@sequenomcm.com
www.sequenomCMM.com
Sequenom CMM® is a wholly owned subsidiary of Sequenom, Inc., and a CLIA-certified, CAP accredited molecular diagnostics laboratory dedicated to the development and commercialization of laboratory-developed tests for prenatal and ophthalmic conditions. Utilizing innovative proprietary technologies, Sequenom CMM provides test results that can be used by ordering clinicians in managing patient care. New for 2012 is the MaterniT21™ PLUS laboratory-developed test, a noninvasive test that analyzes the relative amount of chromosomes 21, 18 and 13 from a maternal blood sample. Other laboratory-developed tests include SensiGene® Cystic Fibrosis Carrier Screening, SensiGene® Fetal RHD Genotyping and RetnaGene™ AMD.

Sharsheret
Booth#: 305
Phone: 866.474.2774
Email: jthompson@sharsheret.org
www.sharsheret.org
Sharsheret is a national not-for-profit organization supporting young women and their families, of all Jewish backgrounds, facing breast cancer. Our mission is to offer a community of support to women diagnosed with breast cancer or at increased genetic risk, by fostering culturally-relevant individualization connections with networks of peers, health professionals and related resources.
WHOLE EXOME SEQUENCING

One Test — More Answers

Developed jointly by the Human Genome Sequencing Center (HGSC), the Department of Molecular and Human Genetics and the Medical Genetics Laboratories of the Baylor College of Medicine, the Whole Genome Sequencing Laboratory (WGL) applies the power of next generation sequencing technology to clinical genetics in a CLIA high complexity testing laboratory with clinical interpretation of the sequence information. Whole Exome Sequencing (WES) is poised to change the current paradigm of genetic testing for Mendelian disorders, pharmacogenetic traits, and potentially complex traits. Rather than limiting testing to a single gene or panel of genes and incurring diagnostic delays and escalating costs, the Whole Exome Sequencing test will sequence nucleotide by nucleotide, the human exome to the depth of coverage required to achieve a consensus sequence with high accuracy. Point mutations, small insertions and deletions of the exome are routinely detected by this methodology. The team curating the Whole Exome Sequencing test focuses the report on known or predicted deleterious mutations in genes associated with patient’s clinical problems; however, significant potentially medically actionable findings in other genes of interest as well as the option for reporting autosomal recessive carrier status are included in the focused whole exome report.